Role of SOX9 in cancer stem cell regulation in lung cancer chemoresistance and particle-induced carcinogenesis by Voronkova, Maria
Graduate Theses, Dissertations, and Problem Reports 
2019 
Role of SOX9 in cancer stem cell regulation in lung cancer 
chemoresistance and particle-induced carcinogenesis 
Maria Voronkova 
mavoronkova@mix.wvu.edu 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
 Part of the Medical Cell Biology Commons 
Recommended Citation 
Voronkova, Maria, "Role of SOX9 in cancer stem cell regulation in lung cancer chemoresistance and 
particle-induced carcinogenesis" (2019). Graduate Theses, Dissertations, and Problem Reports. 4075. 
https://researchrepository.wvu.edu/etd/4075 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
Role of SOX9 in cancer stem cell regulation in lung cancer 
chemoresistance and particle-induced carcinogenesis 
 
 




Dissertation submitted  
to the School of Medicine 
at West Virginia University 
 
 
in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in  




Karen Martin, Ph.D., Chair 
J. Michael Ruppert, M.D./Ph.D. 
Michael Schaller, Ph.D. 
Ivan Martinez, Ph.D. 
HanGang Yu, Ph.D. 
Yon Rojanasakul, Ph.D., Mentor 
 
 









Keywords: chemoresistance, SOX9, cancer stem cells, NSCLC, ALDH 




Role of SOX9 in cancer stem cell regulation in lung cancer 
chemoresistance and particle-induced carcinogenesis  
 
Maria A. Voronkova 
Lung cancer is a leading cause of cancer-related death worldwide. Every year it claims 
more lives than other common malignancies, breast, prostate, and colorectal cancers, 
combined. And despite recent improvements in disease diagnostics and treatment, drug 
resistance and tumor relapse remain major contributors to low patient survival. Both 
issues have been largely attributed to the existence of cancer stem-like cells (CSCs) or 
tumor initiating cells (TICs). CSCs are a small cell population within heterogeneous 
tumors that is inherently resistant to apoptosis, chemo- and radiation therapy. Thus, it is 
critical to elucidate CSC-specific signaling pathways and identify early biomarkers for 
therapeutic intervention. This body of work investigates molecular mechanisms of CSC 
regulation by an embryonic transcription factor SOX9. We show here that SOX9 is 
upregulated upon exposure to cisplatin and positively regulates cancer stem-like 
properties and chemoresistance of non-small cell lung cancer (NSCLC) cells. Moreover, 
we demonstrate for the first time that the stem-cell marker ALDH1A1 is a direct SOX9 
transcriptional target. We also show that SOX9 expression is upregulated in human lung 
epithelial cells chronically exposed to single-walled carbon nanotubes (SWCNT). SOX9 
was identified as a critical factor promoting metastatic and stem-like properties in these 
cells. We also observed a correlation between SOX9 levels and ALDH expression and 
activity in this model of carcinogenesis, suggesting that activation of SOX9-ALDH axis 
may have a broader role in the regulation of cellular stress responses. Taken together, 
our novel findings on the role of SOX9-ALDH axis support the use of this CSC regulator 
as a prognostic marker of cancer chemoresistance and as a potential drug target for 
CSC therapy. The SOX9-ALDH axis could also have a broad role in the regulation of 
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Chapter 1. Introduction and literature review 
 
Lung cancer is the leading cause of cancer-related death worldwide. Non-small 
cell lung cancer (NSCLC) is the predominant type of lung cancer, accounting for up to 
85% of all lung cancer cases (1). NSCLC is traditionally divided into 3 subtypes based 
on histological features: adenocarcinoma (~50% of cases), squamous cell carcinoma 
(~30%) and large cell carcinoma (2). Despite some recent improvements in the disease 
management, 5-year survival rates remain under 20%. Furthermore, over 50% of all 
lung cancer cases in the US are diagnosed when the cancer has already metastasized, 
signifying the need for management of the advanced disease (3). Several types of 
therapy are available for treatment of NSCLC: surgery, radiation, chemotherapy, 
targeted- and immunotherapy; however, surgery is usually not an option for later stages 
(4). Patients who present with stage IV disease undergo molecular testing for driver 
mutations, such as EGFR and BRAF mutations, ALK and ROS1 rearrangements, and 
for programmed death ligand-1 (PD-L1) expression (5). Nevertheless, approximately 
45% of patients with NSCLC have unidentified driver mutations (2, 5, 6), thus platinum-
based chemotherapy is commonly used as a main treatment course or in combination 
with immunotherapy (7). Unfortunately, most patients eventually stop responding to the 
treatment due to development of drug resistance. As a result, delineating the 
mechanisms of drug resistance in lung cancer is of critical importance.  
 
1.1. Carcinogenicity of carbon nanotubes 
 
Risk factors for lung cancer include exposure to tobacco smoke, genetic 
predisposition, exposure to ionizing radiation, air pollution and occupational exposure to 
various carcinogens (8). Engineered nanomaterials have emerged as one of the novel 
sources for environmental and occupational exposure since they have been 
increasingly used for various industrial and biomedical applications. Nanomaterials are 




nanotubes (CNTs) are one of the most widely used nanomaterials due to their unique 
properties such as high tensile strength, flexibility, electrical conductivity, and light 
weight. Common uses of CNTs range from incorporation into rechargeable batteries, 
automotive parts, and sporting goods to water filters (10). Structurally, they represent a 
single or multiple two dimensional graphene sheet(s) rolled into a tube with diameter as 
small as 1 nm and length from few nanometers to microns. 
CNTs exhibit asbestos-like properties, e.g. high aspect ratio (ratio of length to 
width), durability, and biopersistence; therefore, concerns about their potential 
carcinogenicity have been mounting. Accumulating evidence suggests that CNT 
exposure induces genotoxicity and is potentially carcinogenic. Recently, the 
International Agency for Research on Cancer (IARC) classified one type of multi-walled 
carbon nanotubes (MWCNTs) as a possible carcinogen while other MWCNTs and 
single-walled carbon nanotubes (SWCNTs) were considered not classifiable due to 
insufficient evidence at the present time (11). However, several animal studies 
demonstrated that CNTs possess carcinogenic properties. For example, several trans-
tracheal intrapulmonary sprayings of MWCNTs were found to cause malignant 
mesotheliomas, lung adenomas and adenocarcinomas in rats (12). Similar results were 
observed in a more occupationally and physiologically relevant model, where rats were 
exposed to MWCNTs via the whole-body inhalation at 6 hours/day, 5 days/week for 2 
years. Such exposure caused an increase in lung carcinoma incidences in both male 
and female animals (13). A number of in vitro studies investigated possible mechanisms 
of CNT toxicity. Thus, CNTs mimic microtubules and disrupt mitotic spindles causing 
aneuploidy in lung cells (14). Moreover, SWNCT- or MWCNT-exposed small airway 
epithelial cells demonstrate a neoplastic-like phenotype that is more aggressive than the 
asbestos-exposed cells (15). Previous studies by our group have shown that chronic 
exposure to CNTs induces malignant transformation of human lung epithelial cells (15, 
16). These cells exhibit tumorigenic and stem-like properties (17), as well as resistance 
to chemotherapeutic agents (18). The cells also possess defective apoptosis signaling 
pathways and abnormal p53 functions have downregulation of the anti-apoptotic genes 




unknown and regulation of stem properties is poorly understood, which is the subject of 
this investigation. 
 
1.2. Cancer drug resistance 
 
Chemotherapy is one of the major treatment options for cancer patients; 
however, its effectiveness is often hampered by drug resistance. Some tumors are 
intrinsically resistant to drugs while others acquire resistance during treatment. 
Chemoresistant cancer cells are generally less responsive to a wide array of therapeutic 
agents, the phenomenon called multidrug resistance. The molecular mechanisms of 
chemoresistance are complex and involve several adaptive regulatory pathways. While 
certain molecular mechanisms are known, the problem of drug resistance remains a 
major unsolved clinical issue. 
An increase in the activity or the expression of drug efflux pumps has been most 
often attributed to the resistance. The ATP-binding cassette (ABC) transporter family of 
transmembrane proteins transfers a wide variety of xenobiotics, including most 
anticancer drugs, and endogenous substrates, out of cells. Multi-drug resistance protein 
1 (MDR1, P‑glycoprotein or ABCB1), MDR-associated protein 1 (MRP1 or ABCC1) and 
breast cancer resistance protein (BCRP or ABCG2) are the main ABC transporter family 
members implicated in drug resistance, although other ABC transporters may be 
involved (20). These proteins are overexpressed in multiple cancer types and their 
expression correlates with drug resistance and patient survival. Unfortunately, inhibitors 
of ABC transporters have not been successful in clinical trials due to toxicity-related 
issues and a high redundancy between family members (21). Alterations in cellular drug 
influx processes can also contribute to cancer drug resistance. For example, cisplatin is 
actively moved into cells by copper transporter 1 (CTR1) (22) and patients with higher 
CTR1 levels have better treatment outcomes after a platinum-based therapy (23).  
Another common mechanism of drug resistance is drug target alterations, such 
as mutations or changes in expression levels. For instance, mutations in tubulin are 




while decreased expression of topoisomerase II promotes cancer cell survival after 
treatment with topoisomerase II inhibitors. Many chemotherapeutic drugs induce direct 
or indirect DNA damage that leads to apoptosis if not repaired. Remarkably, cancer 
cells can modulate DNA damage response pathways, avoiding apoptosis and activating 
several pro-survival pathways (21). 
In summary, multiple mechanisms of cancer chemoresistance have been 
identified. Intrinsic resistance implies that tumors already have certain characteristics 
that cause chemotherapy failure while acquired resistance emerges during and after 
treatment. A number of theories explain how acquired chemoresistance occurs, such as 
new mutations arising during treatment, cell plasticity leading to adaptation, and a 
therapy-induced selection of already resistant cells from originally heterogeneous 
tumors (24). 
1.3.  Cancer stem cell theory 
Increasing evidence suggests that cancer stem cells (CSCs) or tumor initiating 
cells are the main source of tumor dissemination, chemotherapy resistance, and 
subsequent recurrence (25, 26). According to CSC theory, CSCs are a small population 
of cells sharing certain properties with regular stem cells, such as proliferation, 
clonogenicity (27), and the ability to self-renew and give rise to all other cells that make 
up a tumor (28-31). However, these cells are also highly resistant to apoptosis and 
drugs, and are highly tumorigenic, i.e. a single CSC has the potential to produce a 
tumor in vivo (32) (Figure 1). Therefore, serial dilutions of cells as well as serial 
xenotransplantations have been used as a gold standard for proving CSC properties 
(33, 34). Furthermore, CSCs are also termed tumor initiating cells (TIC) due to their 
ability to produce tumors and metastasize; however, the exact terminology remains a 
debated topic (24). Another highly discussed theory is the origin of CSCs: do these cells 
arise from mutated adult stem cells, progenitor cells or from differentiated cells? 
Moreover, accumulating evidence indicates that CSCs are highly plastic and can 
reversibly transition between stem and non-stem states (35-37).  
CSCs can be characterized and isolated based on a number of stem cell 




CD44, CD133, ALDH1 expression as well as ALDH activity measured by Aldefluor® 
assay, and ABCG2 drug efflux activity, evaluated by side population assay, are widely 
used to identify CSCs in solid tumors (25). Moreover, CSCs express multiple embryonic 
transcription factors, including SOX2, Oct4, and Nanog (38), which have also been used 
to characterize CSCs. However, each subtype of CSCs isolated and/or characterized 
based on one set of markers displays a unique phenotype and properties that only 
partially overlap with other CSC subtypes (39, 40). For example, breast CSCs can exist 
in mesenchymal-like state identified as quiescent and CD24-CD44+ and in more 
proliferative epithelial-like state characterized by high ALDH1 expression and activity 
(41). 
Figure 1. Properties and potential roles of cancer stem cells. 
 
CSCs are inherently more resistant to cytotoxic therapy as compared to regular 
cancer cells due to many mechanisms, including slower proliferation, high expression of 
drug efflux pumps, and higher levels of detoxification and DNA repair activities (42-44). 
Thus, it is not surprising that the conventional chemotherapy kills the bulk of tumor cells 
but spares CSCs, leading to cancer recurrence (45-47). Multiple attempts have been 
made to target CSCs: inhibitors of CSC signaling pathways, antibodies against CSC 




However, the results are mixed or applicable only to certain tumor types due to high 
CSC plasticity, similarity to adult stem cells, and limited knowledge on CSC biology (34). 
Therefore, it is critical to identify specific pathways and mechanisms controlling CSC to 
successfully eliminate them. 
1.3. SOX9 
SOX9 in development and normal physiology 
 
Many developmental proteins are now being recognized as oncogenes due to 
their ability to regulate not only stem cells but also CSCs. SOX9 (SRY (sex determining 
region Y)-box 9) is a member of the conserved high‐mobility group (HMG)‐box class of 
transcription factors. SOX9 works downstream of SRY (sex-determining region Y) to 
initiate mammalian male sex determination. Germline SOX9 mutations cause 
campomelic dysplasia, a severe, generally lethal developmental condition, 
characterized by cartilage and bone malformations, and common male sex reversal or 
ambiguous genitalia (48), while heterozygous mice die hours after birth due to multiple 
skeletal malformations (49). Consistently, SOX9 is essential for chondrocyte 
proliferation and early differentiation (50). Furthermore, this transcription factor controls 
critical stages in the development of many organs, including heart, intestine, pancreas, 
and central nervous system, where it regulates stem cell homeostasis and 
differentiation. In adults, SOX9 is expressed in stem cells in multiple tissues, including 
central nervous system, skin, intestine, liver and pancreas (48, 51, 52). In lungs, SOX9 
regulates branching morphogenesis during embryonic development and a response to 
injuries in adults (53, 54). Consistent with its role in embryonic development, SOX9 
expression is reactivated during chronic inflammation and tissue damage which may 




Structure of SOX9 and regulation of its activity 
Figure 2. Structure of SOX9 protein. 
DIM - dimerization domain; HMG - DNA-binding high mobility group domain; K2, TA - 
transactivation domains; NLS - nuclear localization sequences; NES - nuclear export 
sequence; PQA - proline, glutamine and alanine-rich domain; phosphorylation sites 
(red), and ubiquitination/sumolyation sites (blue). Reproduced from (48) under the CC 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). 
 
Structurally, SOX9 contains a DNA-binding high mobility group (HMG) domain, 
which is highly conserved among SOX proteins, a self-dimerization domain, two 
transactivation domains, and the proline, glutamine and alanine (PQA) domain, whose 
function is not known (Figure 2). The HMG domain of SOX9 also contains two nuclear 
localization sequences and a nuclear export signal to allow for the protein to be shuttled 
between the nucleus and the cytoplasm (48). SOX9 binds to a consensus DNA 
sequence, AACAAT, shared with other SOX proteins, while two flanking nucleotides 
from both sides of this sequence determine the binding specificity of SOX proteins (55). 
Notably, several recent studies utilizing ChIP-seq assay have identified novel SOX9 
binding motifs (Table 1), indicating that SOX9 binding may be tissue specific or context 
dependent. Moreover, SOX9 can bind its targets as a dimer, which is more common in 
chondrogenesis, or as a monomer, as proposed in the case of sex differentiation (56) 
and other non-chondrocyte specific gene targets (57). This transcription factor also 
cooperates with other SOX family members, SOX5 and SOX6, on promoters of several 
chondrocyte‐specific genes (58, 59). Additionally, SOX9 was shown to heterodimerize 
with SOX8 or SOX10 but not with other SOX proteins in a way involving the DNA-
binding domain of one binding partner and the dimerization domain of another (60). A 
different mode of SOX9 action involves cooperation with a different transcription factor, 
NF-Y, when SOX9 does not bind to DNA directly but is critical for transcription activation 




SOX9 may regulate alternative splicing and that splicing targets are different from the 
SOX9 transcriptional targets (62).  




CATTCATG In vitro (63) 
AGAACAATGG In vitro (55) 
 
 





















Limited information is available about the direct transcriptional targets of 
SOX9. The transcription factor can work as a transcriptional activator or repressor, 
depending on cellular context. For instance, SOX9 cooperates with Gli proteins to 
repress gene transcription of Col10a1 and to inhibit chondrocyte maturation but forms a 
complex with Sox5/6 to activate the transcription of Col2a1, which is involved in 
extracellular matrix (ECM) deposition and chondrocyte differentiation (58, 67). SOX9 
regulates the expression of stemness genes TCF3, TCF4 and HMGA2 in basal cell 
carcinoma (64) and was proposed to regulate cell proliferation and senescence by 
activating p21(cip1), an inhibitor of cell cycle progression (68, 69). Conversely, SOX9 is 
recruited by NF-Y to promoters of cell cycle regulatory genes, such as cyclin B1 
(CCNB1), cyclin B2 (CCNB2), cyclin dependent kinase 1 (CDK1), and topoisomerase II 
(TOP2A), and is critical for expression of these proteins in colorectal cancer (61). 
Several signaling pathways leading to SOX9 activation have been identified in 
developmental biology, such as Sonic hedgehog, Notch, Wnt and others (48, 70). 
Accumulating evidence also suggests that similar pathways are involved in SOX9 
overexpression during carcinogenesis (summarized in Table 2). Other studies showed 
that SOX9 can be phosphorylated by GSK3 kinase, targeting SOX9 for subsequent 
ubiquitination and proteasomal degradation (71, 72). In addition, SOX9 forms an 





Table 2. Signaling pathways involved in the regulation of SOX9 expression and 
activity 




cancer cell lines 
















Mouse chondrocytes Repression by β-catenin (78) 
Human colon cancer, 
mouse intestine 
Activation by unknown 
mechanism 
(79) 
Wnt, BMP Chick embryos 
Phosphorylation leading to 
SUMOylation activate 
interactions with Slug 
(80) 
TGFβ 
Mouse chondrogenic cell 
line, human 
chondrosarcoma cell line 
Phosphorylation and 
stabilization by p38 and 
Smad2/3, stabilization at 
transcription site by Smad2/3 
(81) 
(82) 
Rat kidney fibroblasts 
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SOX9 in cancer 
 
SOX9 has been implicated in the formation and progression of multiple cancer 
types (89). It is overexpressed in various solid tumors, such as breast, prostate, 
pancreatic and lung cancers. Furthermore, SOX9 overexpression positively correlates 
with poor overall and disease-free survival in these malignancies (90, 91). Interestingly, 
contradictory results on the prognostic role of SOX9 overexpression have been reported 
in melanoma (92, 93). However, a study by Yang et al. showed that low SOX9 
expression restricts metastasis while its high expression promotes it (94). Similar dose-
dependent action was proposed for SOX9 in colorectal cancer (95), explaining 
contradictory reports on tumor suppressing and oncogenic properties of this 
transcription factor. For instance, high SOX9 levels predict low risk of relapse in stage II 
colon cancer patients (96) and inhibits proliferation of colorectal cell lines (97). In 
contrast, SOX9 promotes invasion, migration and tumor formation in colorectal cells and 
correlates with lower 5-year survival in patients according to other studies (98, 99). An 
integrating model, proposed by Prevostel et al., suggests that there is a critical level of 
SOX9 required for optimal proliferation of colorectal cells while too low or too high SOX9 
expression would inhibit cell growth (97).  
SOX9 promotes acinar-to-ductal reprogramming and is required for oncogenic 
KrasG12D-mediated induction of premalignant lesions in pancreatic ductal 
adenocarcinoma (PDAC) (100). Kras, in turn, induces SOX9 expression, protein 
stability, nuclear translocation, and activating phosphorylation. SOX9 levels are 
increased via TAK1-kinase and may form a positive feedback loop with NF-κB pathway 
in PDAC (84). Moreover, NF-κB subunit p65 can directly regulate transcription from the 
SOX9 promoter (85). SOX9 has also been recently identified as a part of the Wnt/β-
catenin-related signature in driver gene-negative (for known driver mutations) lung 
adenocarcinoma. Patients identified as a high-risk cohort, defined by high SOX9, β-
catenin, DVL3 and low Wnt2b expression, had a substantial decrease in overall 





Other studies demonstrated that SOX9 promotes cancer stem-like properties in 
multiple tumor types. SOX9 has been shown to stimulate self-renewal and to inhibit cell 
differentiation in basal cell carcinoma (64). This transcription factor is also highly 
expressed in liver CSCs and controls self-renewal and symmetrical cell division, 
promoting tumorigenicity in hepatocellular carcinoma (102). It also cooperates with the 
master – regulator of epithelial-to-mesenchymal transition (EMT) Slug to maintain 
normal mammary stem cells and breast CSCs, and to reprogram differentiated breast 
cells into stem cells (103). In lungs, SOX9 expression is associated with stemness of 
lung carcinoma (104), although the underlying mechanisms are not known. SOX9 was 
shown to promote invasion in pancreatic cancer (85). 
A few reports suggest that SOX9 may enhance chemoresistance; however, the 
exact molecular mechanisms and downstream effectors remain unknown. For instance, 
Santos et al. (105) observed a correlation between SOX9 expression and a response to 
cisplatin in gastric cancer cells. These results were supported by knockdown and 
overexpression experiments in this model and in medulloblastoma (72). Consistent with 
preclinical studies, SOX9 overexpression in colorectal cancer correlated with poor 
survival in 5-FU treated patients but not in untreated patients (106). Strong SOX9 
expression in breast cancer after chemotherapy was associated with short overall 
survival (107). While the association between SOX9 expression and chemotherapeutic 
efficacy has been reported, the underlying mechanisms of SOX9-mediated 
chemoresistance remain largely unknown. 
1.4.  ALDH 
The aldehyde dehydrogenase (ALDH) superfamily of NADP+-dependent 
enzymes includes 19 members in humans and catalyzes the oxidation of various 
aldehydes into corresponding carboxylic acids. The enzymes detoxify endogenous 
aldehydes, generated during normal cellular metabolism, as well as exogenous 
aldehydes, generated from the exposure to environmental agents and drugs (108). Most 
isoforms are widely distributed throughout the body and can be localized to the cytosol, 
mitochondria, peroxisomes and/or nucleus. While individual ALDH enzymes have 




It is worth noting a number of discrepancies regarding ALDH nomenclature in the 
literature. Thus, the term ALDH1 or ALDH could be utilized to define any member of the 
ALDH1 subfamily (e.g. ALDH1A1, 1A2, 1A3, 1B1, 1L1, 1L2) but often used to describe 
ALDH1A1 specifically (110). Another controversy arises with respect to the standard 
method to evaluate ALDH activity, Aldefluor® assay. The assay is based on the 
fluorescent ALDH substrate, BODIPY-amino acetaldehyde (BAAA), which passively 
diffuses into cells but is retained intracellularly after being converted into a negatively 
charged product by ALDH. This assay was first employed to isolate hematopoietic stem 
cells (111) but is currently used to characterize and isolate both normal and CSCs. The 
Aldefluor® assay was considered ALDH1A1 specific, but recent reports suggest that it 
detects the activity of several or predominantly expressed organ- and tissue-specific 
ALDH isoforms (112, 113). 
Aldehyde dehydrogenases in cancer 
 
While all group members participate in the detoxification of endogenous and 
exogenous agents, ALDH1A1 is particularly known as a CSC marker in multiple cancer 
types (114). Isolated ALDHhigh cells are extremely tumorigenic and display an increased 
ability to colonize distant organs (115). Moreover, ALDH1A1 is overexpressed in many 
cancer types and usually correlates with poor prognosis. For example, high ALDH1 
expression correlates with poor overall survival in ovarian cancer (116). While individual 
reports do not agree on the prognostic value of ALDH1A1 overexpression, meta-
analysis studies demonstrate a strong correlation between ALDH1 expression and 
overall and disease-free survival in lung cancer (117, 118), colorectal cancer (119), and 
head and neck squamous cell carcinomas (120).  
ALDH1A1 was shown to regulate cell proliferation and drug resistance (109, 
121). Moreover, elevated ALDH1 expression after neoadjuvant chemotherapy is 
associated with poor response and early relapse in ovarian, breast and esophageal 
cancers (122-124). ALDH1A1 is also overexpressed in many drug-resistant cell lines 
(125-127), suggesting that it plays a role in chemoresistance.  
In addition to serving as a stem cell marker, ALDH governs CSC differentiation 




convert retinaldehyde into retinoic acid (RA). Retinoic acid binds to its nuclear receptor 
followed by attachment to retinoic acid response elements on the promoter of target 
genes and induces stem cell differentiation (129). Remarkably, all-trans retinoic acid 
(ATRA) has been successfully used in the treatment of acute promyelocytic leukemia 
(APL) in combination with chemotherapy but was not effective for other tumor types 
(130, 131). 
 
Figure 3. Summary of ALDH1A1 regulation and functions 
Reproduced from (132) under the Creative Commons Attribution License. 
 
 
High ALDH activity, which is typical for stem cells, could also support CSC 




cyclophosphamide, 4-hydroxycyclophosphamide (4-HC), and therefore directly protect 
cancer cells from the drug (133, 134). A recent study also reported that ALDHhigh cells 
exhibit low ROS levels relative to ALDHlow counterparts (135). In addition, ALDH 
inhibition leads to an accumulation of toxic ROS in targeted-therapy selected CSCs, 
suggesting that the high ALDH activity is vital for CSC survival (136). NADH production 
by ALDH enzymes has also been proposed as a source of increased ATP synthesis 
and therefore cancer cell survival in NSCLC (137). Furthermore, ALDH1A1 stimulates 
the activity of NRF2, a key regulator of cellular antioxidant response (138). 
It becomes evident that not only ALDH1A1 but other ALDH isoforms contribute to 
the malignant properties and to chemotherapy resistance of CSCs (Table 3). For 
example, high ALDH3A1 and ALDH1A3 expression is associated with lung cancer 
progression (139, 140). Moreover, ALDH1A3 is the main isoform responsible for the 
increased ALDH activity in breast cancer (141). Interestingly, while ALDH1A3 
contributes to the Aldefluor® activity in breast cancer, ALDH1A1 controls the metastatic 
and drug resistance properties of the cells (142), suggesting a potential functional 
cooperation between the isoforms.  
Table 3. Functions of ALDH isoforms other than ALDH1A1 in cancer 
Isoform Experimental evidence Reference 
ALDH1A2 
RA production, knockdown induces sensitivity to 1-β-D-
arabinofuranosylcytosine (AraC) in leukemic cells, 
overexpression induces cell proliferation, higher 
clonogenicity and resistance to doxorubicin and 4-HC in 





RA production, increases survival and drug resistance in 
mesothelioma, enhances growth of glioma CSCs. 
ALDH1A3 knockout decreases clonogenicity of 
neuroblastoma CSCs, ALDH1A3 knockdown induces 
apoptosis and inhibits xenograft growth in melanoma, 
inhibits clonogenicity and tumor formation in in vivo 








Knockdown inhibits clonogenicity and tumor growth in 










Knockdown inhibits metastases but not primary tumor 
growth in melanoma xenografts 
(153) 
ALDH2 
Overexpression induces cell proliferation, higher 
clonogenicity and resistance to doxorubicin and 4-HC in 
leukemic and NSCLC cells 
(145) 
ALDH3A1 
Knockdown increases sensitivity to 4-HC in NSCLC 
cells, pharmacological inhibitions sensitize NSCLC and 








Overexpression in HEK293 cells protects against 
oxidative stress 
(157) 
ALDH3B2 Functions unknown (109) 
ALDH4A1 
Overexpression in NSCLC cells reduces ROS under 




Pharmacological inhibition inhibits cell proliferation in 
breast cancer cells in 3D culture 
(159) 
ALDH6A1 




Knockdown decreases metastasis and CSC population 
in prostate cancer 
(161) 
ALDH8A1 RA production (108) 
ALDH9A1 
No known functions in cancer, involved in GABA 
biosynthesis 
(108) 
ALDH16A1 Functions unknown (109) 
ALDH18A1 
Highly expressed in breast cancer cells sensitive to 
glutaminase inhibitor  
(162) 
 
Regulation of ALDH expression and activity 
 
Limited information about ALDH regulation in CSCs is available, and most 
studies to date have focused on ALDH1A1 isoform (Figures 3 and 4). ALDH1A1 




β (C/EBPβ) transcription factor (163) and by Wnt pathway through β-catenin (164). 
However, high levels of retinoic acid downregulate C/EBPβ and therefore create a 
negative feedback loop with ALDH1 (165). Interestingly, contradictory results on the role 
of TGFβ signaling in ALDH1A1 regulation suggest cell context-dependent functions. For 
example, Hoshino et al. reported transcriptional repression of ALDH1A1 by Smad4 
(166) in pancreatic cancer, while a treatment with TGF-β1 induced the number of 
ALDH-positive cells and ALDH1 expression in cholangiocarcinoma (167) and ALDH-
positive population in breast cancer (168). Moreover, TGF-β2 treatment decreased 
ALDHhigh population in clear-cell renal cell carcinoma (169), suggesting a relationship 
between TGFβ signaling and ALDH expression which requires further investigations.  
Figure 4. Regulation of ALDH1 expression and activity 
 
ALDH1A1 activity can be regulated by post-translational modifications. For 
instance, it is induced by Notch signaling through deacetylation of the enzyme (170). 
Furthermore, phosphorylation by Aurora kinase A (AURKA), a protein essential for 






Lung cancer is the leading cause of cancer-related mortality with platinum-based 
chemotherapy commonly used as a main treatment course. Unfortunately, most patients 
eventually stop responding to the treatment due to development of drug resistance. And 
while certain molecular mechanisms are known, the problem of drug resistance remains 
a major unsolved clinical issue. It has been noticed that the conventional chemotherapy 
spares a population of cancer cells, displaying stem-like properties, which are called 
cancer stem cells or tumor-initiating cells. Since these cells are generally resistant to 
chemotherapy and radiation, they eventually give rise to recurrent tumors; hence there 
is a pressing need to identify markers and potential drug targets, specific to this cancer 
cell population. Our work is focused on understanding the role of SOX9 in lung CSC 
regulation and elucidating the underlying mechanisms. SOX9 have been shown to 
regulate CSCs in several types of cancer but the exact mechanisms and downstream 
targets are largely unknown. Moreover, there is little information on role of SOX9 in 
response to chemotherapy. In this work, we sought to determine the functional role of 
ALDH1A1 as a direct transcriptional target of SOX9 and as a key mediator of drug-
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Chemotherapy resistance and tumor relapse are the major contributors to low patient 
survival, and both have been largely attributed to cancer stem-like cells (CSCs) or tumor 
initiating cells (TICs). Moreover, most conventional therapies are not effective against 
CSCs, which necessitates the discovery of CSC-specific biomarkers and drug targets. 
Here, we demonstrated that the embryonic transcription factor SOX9 is an important 
regulator of acquired chemoresistance in non-small cell lung cancer (NSCLC). Our 
results showed that SOX9 expression is elevated in NSCLC cells after treatment with 
the chemotherapeutic cisplatin and that overexpression of SOX9 correlated with worse 
overall survival in lung cancer patients. We further demonstrated that SOX9 knockdown 
increases cellular sensitivity to cisplatin, whereas its overexpression promotes drug 
resistance. Moreover, this transcription factor promotes stem-like properties of NSCLC 
cells and increases their ALDH activity, which was identified as the key mechanism of 
SOX9-induced chemoresistance. Finally, we showed that ALDH1A1 is a direct 
transcriptional target of SOX9 based on chromatin immunoprecipitation and luciferase 
reporter assays. Taken together, our novel findings on the role of SOX9-ALDH axis 
support the use of this CSC regulator as a prognostic marker of cancer 







SOX9 is a member of the high‐mobility group (HMG)‐box class of transcription 
factors and controls critical stages in embryonic development, stem cell homeostasis 
and differentiation. Germline SOX9 mutations cause severe cartilage and bone 
malformations, and male sex reversal (1). In adults, SOX9 is expressed in stem cells in 
multiple tissues, including central nervous system, skin, intestine, liver and pancreas (1-
3). In lungs, SOX9 regulates branching morphogenesis during embryonic development 
and a response to injuries in adults (4, 5). SOX9 has also been implicated in the 
formation and progression of multiple cancer types (6). It is overexpressed in various 
solid tumors, such as breast, prostate, pancreatic and lung cancers. Furthermore, SOX9 
overexpression positively correlates with poor overall and disease-free survival in these 
malignancies (7, 8), which could be due to its effect on tumor initiating cells or cancer 
stem cells (CSCs). 
CSCs are a small tumor cell population that is highly tumorigenic and generally 
resistant to apoptosis, chemo- and radiation therapy, thus thought to be a major source 
of drug resistance and recurrence in cancer (9). As imbalance of stem cell homeostasis 
and differentiation may contribute to tumorigenesis, many stem cell transcription factors, 
including SOX9, have been linked to CSC regulation. Indeed, SOX9 has been shown to 
promote self-renewal and inhibit cell differentiation in basal cell carcinoma (10). This 
transcription factor is also highly expressed in liver CSCs and controls self-renewal and 
symmetrical cell division, promoting tumorigenicity in hepatocellular carcinoma (11). In 
lungs, a recent study by our group showed that SOX9 expression is associated with 
stemness of lung carcinoma as indicated by their side population and sphere formation 
properties (12), although the underlying mechanisms are not known. 
Consistent with its role in CSC regulation, increasing evidence suggests that 
SOX9 may play a role in chemotherapy resistance (13-16). However, a detailed 
understanding of the process remains to be elucidated. We hypothesized that SOX9 
plays a role in lung cancer progression and chemoresistance by inducing cancer stem-




positively regulates cancer stem-like properties and chemoresistance of NSCLC cells. 
Moreover, we demonstrated for the first time that the stem-cell marker ALDH1A1 is a 







High SOX9 expression correlates with poor survival in NSCLC patients and is 
induced by cisplatin exposure in human lung cancer cells 
SOX9 is reported to be overexpressed in a number of cancer types, including 
lung cancer. We analyzed The Cancer Genome Atlas (TCGA) NSCLC patient cohort to 
determine whether SOX9 overexpression could predict patient survival. Indeed, higher 
SOX9 expression correlates with poor overall survival in adenocarcinoma and 
squamous cell carcinoma, two major histological types of NSCLC (Figure 1A, B). SOX9 
is overexpressed in tumors compared to normal tissues in patient samples (17, 18). 
Consistent with these data, we found that SOX9 expression is highly upregulated in 
most NSCLC cell lines as compared to primary lung epithelial cells and several non-
tumorigenic lung epithelial cell lines (Figure 1C). Together, these observations support 
the role of SOX9 in lung cancer progression. 
Multiple studies have reported an increased expression of several stem cell 
markers in drug resistant cells (19-21). We tested whether SOX9 expression is 
upregulated in lung cancer cells in response to cisplatin treatment. NSCLC cells H460, 
A549 and H1299 were treated with cisplatin at the IC50 concentrations and analyzed for 
SOX9 expression by RT-qPCR and Western blotting. Figures 1D and 1F show that 
SOX9 protein and mRNA levels were highly elevated following a 2-3-day exposure to 
the drug. Furthermore, these cells become highly resistant to cisplatin upon subsequent 
exposures (Figure 1E, Suppl. Fig. 1A), suggesting a potential role of SOX9 in resistance 
to cisplatin. 
SOX9 overexpression promotes chemoresistance in NSCLC cells 
Next, we examined the effects of SOX9 overexpression and knockdown on cell 
survival upon treatment with chemotherapeutic drugs. Our results showed that SOX9 
knockdown in two NSCLC cell lines, H460 and A549 (see Suppl. Fig. 1 for knockdown 
and overexpression levels), increased drug sensitivity (Figure 2A, Suppl. Fig. 1B, C), 
whereas SOX9 overexpression reduced the sensitivity of these cells (Figure 2B, C). 




results (Suppl. Fig. 1D, E), indicating a broad role of SOX9 in cell survival upon drug 
exposure. While the standard cell viability assay provides a valuable insight into an 
acute cellular response to drugs, evaluating a more prolonged effect of drug exposure is 
more clinically relevant with regards to the development of resistance. Thus, colony 
formation assay is often used as a surrogate for long-term cell survival after drug 
treatment. In this study, we pre-exposed the cells to cisplatin for 2 days, let them 
recover for 4 days in drug-free media, and then the cells were plated at a very low 
density for colony formation. The number of colonies formed by the cisplatin-treated 
cells was normalized to that of untreated cells to account for any initial differences in 
colony formation caused by SOX9 knockdown. Our results showed that SOX9 
knockdown significantly reduced the number of colonies as compared to vector control 
(Figure 2D), while SOX9 overexpression promoted the colony formation (Figure 2E). 
These observations are consistent with the cell viability results and indicate a positive 
regulatory role of SOX9 in drug resistance of NSCLC cells. 
SOX9 positively regulates cancer stem-like properties of NSCLC cells 
A growing body of evidence suggests that a particular cancer cell population, 
namely CSCs, may be responsible for therapeutic resistance and tumor relapses (22). 
We therefore investigated the role of SOX9 as a CSC regulator in NSCLC cells. First, 
tumor sphere formation was performed in SOX9 knockdown and overexpressing cells. 
Sphere formation assay is widely used to evaluate multipotency and self-renewal of 
stem cells in normal and cancerous tissues and serves as a measure for CSC 
frequency in vitro (23, 24). We found that the tumor sphere formation was substantially 
reduced in SOX9 knockdown cells (Figure 3A); whereas it was enhanced in 
overexpression experiments (Figure 3B). This effect was also retained during the 
formation of secondary spheres (Figure 3C), confirming that SOX9 positively regulates 
self-renewal properties of NSCLC cells. In line with these results, pluripotency-
associated transcription factors Oct3/4, Nanog, SOX2 and KLF4 (25) were suppressed 
in SOX9 knockdown cells (Figure 3D, Suppl. Fig. 3B). Importantly, SOX9 confers 
cisplatin resistance under stem cell-selective conditions during sphere formation (Figure 




CSCs. This result cannot be explained by the initial difference in cell proliferation, since 
tumor sphere formation in the presence of the drug was normalized to that of untreated 
cells. In addition, SOX9 overexpressing cells grew slower than the control cells (Suppl. 
Fig. 2C). Collectively, these observations indicate that high SOX9 expression is 
associated with stem-like properties of NSCLC cells. 
ALDH1A1 is a downstream target of SOX9 and regulates chemoresistance 
In search for the underlying mechanisms of CSC regulation by SOX9, we 
observed a dramatic decrease in ALDH1A1 expression in SOX9 knockdown cells 
(Figure 4A). The aldehyde dehydrogenase isoform ALDH1A1 belongs to a group of 
aldehyde oxidizing enzymes that includes 19 members in humans (26). While all group 
members participate in detoxification of endogenous and exogenous products of 
metabolism, ALDH1A1 is particularly known as a universal CSC marker (27). 
Furthermore, ALDH1A1 was shown to regulate cell proliferation and cancer drug 
resistance (28-30). Thus, we evaluated ALDH1A1 as a potential downstream effector of 
SOX9. Consistent with the knockdown experiments, SOX9 overexpression upregulated 
ALDH1A1 at the protein (Figure 4B) and mRNA (Figure 4C) levels. Moreover, ALDH 
enzymatic activity, measured by the flow cytometry-based Aldefluor® assay, was also 
elevated upon SOX9 overexpression (Figure 4D). We also profiled mRNA levels of all 
19 human ALDH isoforms in SOX9 knockdown cells since the Aldefluor® assay 
appears to be not isoform-specific (31, 32). Our results showed that only ALDH1A1 
expression was suppressed by SOX9 knockdown (Figure 4E), further suggesting that 
ALDH1A1 acts downstream of SOX9.  
We next evaluated the role of SOX9-mediated ALDH1A1 upregulation in drug 
resistance. We observed that ALDH1A1 expression is elevated during cisplatin 
treatment (Figure 5A) and that inhibition of ALDH activity by a known ALDH blocker N, 
N-diethylaminobenzaldehyde (DEAB) reduced cell viability upon exposure to the drug 
(Figure 5B, Suppl. Fig 3A). Furthermore, the ALDH inhibitor reversed the effect of SOX9 
overexpression on cisplatin resistance (Figure 5C), suggesting that SOX9 mediates its 




ALDH1A1 is regulated by SOX9 at the transcriptional level 
Next, we investigated the underlying mechanism of ALDH1A1 regulation by 
SOX9. A time-course study of ALDH1A1 expression in cells with doxycycline-inducible 
SOX9 overexpression was conducted first. Interestingly, ALDH1A1 expression was 
upregulated as early as 4 hours after doxycycline was added (Figure 6A), suggesting 
that SOX9 may induce ALDH1A1 expression at the transcription level. We next 
performed chromatin immunoprecipitation (ChIP) followed by qPCR analysis. Validated 
primers for a known SOX9 target COL2A1 (33) were used as a positive control for 
SOX9 antibody while several primer sets were designed for the ALDH1A1 promoter 
(Figure 6B). In support of the previous results, SOX9 binding was enriched at several 
promoter locations, but not in intron 1, 4.5kb downstream of the transcription start site 
(Figure 6C). To further assess whether SOX9 could directly activate transcription from 
the ALDH1A1 promoter, we performed luciferase reporter assay. Cells were transfected 
with an empty luciferase reporter plasmid or a reporter plasmid containing 1kb long 
ALDH1A1 promoter (Figure 6B). A substantial increase in luciferase signal was 
observed in SOX9 overexpressing cells in comparison to vector control cells (Figure 
6D). A similar result was observed in HEK293 cells transfected with both SOX9 and 
luciferase reporter plasmids (Suppl. Fig 3C). Collectively, our observations indicate that 







Non-small cell lung cancer (NSCLC) is the second most common cancer in both 
men and women and a leading cause of cancer-related death worldwide. It claims 
around 150,000 lives yearly in the U.S. alone (34). Despite recent advances in cancer 
therapy, chemotherapy remains a vital component of the overall treatment strategies for 
lung cancer. However, patient survival continues to be poor due to intrinsic and newly 
acquired drug resistance, which is an unresolved clinical problem. We identified SOX9 
as a potential regulator of cancer cell survival during chemotherapy based on its ability 
to regulate chemoresistant CSCs. We also observed a dramatic increase in SOX9 
levels in cisplatin-treated cells. In contrast, Hong et al. (14) reported that SOX9 was 
degraded by cisplatin and other DNA damaging agents such as doxorubicin. This 
apparent contradiction may be explained by the fact that the latter study used extremely 
high drug concentrations (e.g. 30 μM for cisplatin and 7.4 µM for doxorubicin) and a 
short exposure time that could result in different cellular responses from those observed 
in this study. In another report, SOX9 expression was found to be upregulated in gastric 
cell lines after a low-dose (10 μM) long-term (5-day) exposure to cisplatin (13). This 
result is consistent with our findings in lung cancer cells and suggests that SOX9 
upregulation may be important for cancer cell survival under a selective therapeutic 
pressure. This notion is supported by clinical data showing a poor survival outcome in 
patients with high SOX9 expression (Figure 1A; (7))  
Our major objective was to uncover a mechanism by which SOX9 mediates its 
effect on chemoresistance. We showed that ALDH1A1 (also identified as ALDH1), 
which is a common biomarker for normal and cancer stem cells, is a direct 
transcriptional target of SOX9. According to the cancer stem cell theory, tumors contain 
a small population of cells that is highly tumorigenic, drug- and apoptosis resistant and 
possesses stem-like properties such as the ability to self-renew and differentiate (9). 
The human ALDH family of proteins includes 19 members but ALDH1A1 is the main 
isozyme used to identify and/or isolate normal and cancer stem cells in multiple tissues 
(30). ALDH1A1 is overexpressed in many cancer types and usually correlates with poor 




ovarian cancer (35). Moreover, elevated ALDH1 expression after neoadjuvant 
chemotherapy is associated with poor response and early relapse in ovarian, breast and 
esophageal cancers (36, 37). While individual reports do not always agree on the 
prognostic value of ALDH1A1 overexpression, meta-analysis studies demonstrated a 
strong correlation between ALDH1 expression and overall and disease-free survival in 
lung cancer (38, 39), colorectal cancer (40) and head and neck squamous cell 
carcinomas (41). Other studies showed that ALDH1A1 is overexpressed in drug-
resistant cell lines (19, 29, 42). Furthermore, high ALDH activity, typical for stem cells, 
could support CSC survival. For instance, ALDH1A1 can detoxify an active derivate of 
cyclophosphamide, 4-hydroxycyclophosphamide, and therefore directly protect cancer 
cells from drugs (43, 44). A recent study also reported that ALDHhigh cells have lower 
ROS levels than their ALDHlow counterparts (45). Taken together, these results indicate 
that ALDH1A1 upregulation in response to cytotoxic stress supports CSC survival. Our 
findings further demonstrated that this process is regulated, at least in part, through 
SOX9 overexpression. 
While we focused our attention on ALDH1A1, other ALDH isoforms may 
contribute to CSC properties in general and to chemotherapy resistance in particular. 
For example, high ALDH3A1 and ALDH1A3 expression was also reported in lung 
cancer (46, 47). However, unlike ALDH1A1, these isoforms are not a direct target of 
SOX9 based on our knockdown studies (Figure 4E). We also considered other possible 
roles of SOX9 in the regulation of cell survival and chemoresistance. It has been 
suggested that the decreased survival of SOX9 knockdown cells in long-term 
experiments (i.e. in colony formation or tumor sphere formation assays) may be due to 
a slower rate of cell proliferation (6). However, SOX9low cells were more sensitive to 
drug treatment even after taking into account the initial effect of knockdown in untreated 
cells, and the opposite is true for the overexpression experiments (Figure 2D, E, 3E). 
Furthermore, ectopic expression of SOX9 decreased the rate of cell proliferation while 
promoting the survival of drug-treated cells (Suppl. Fig. 1D, E, 2C).  
In summary, we demonstrated the role of SOX9 in CSC regulation and drug 




expression, which is crucial to their long-term survival and resistance to chemotherapy. 
SOX9 mediates its effect on cisplatin resistance through transcriptional activation of 
ALDH1A1. This novel finding supports the use of SOX9 as a prognostic marker of 






Materials and methods 
Cell culture and drugs. H460 (NCI-H460), Beas-2B, HBEC3-KT, H1299, H358, H1650 
and A549 cells were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) and were passaged less than 15 times. H460 cells were 
maintained in RPMI medium (Corning, Corning, NY, USA) supplemented with 10% 
FBS; A549, H1299, H358, H1650 cells were cultured in DMEM medium (Corning) 
supplemented with 10% fetal bovine serum (FBS). Beas-2B and HBEC cells were 
cultured in BEBM medium supplemented with Clonetics BEGM BulletKit (Lonza, 
Walkersville, MD, USA). Primary human SAECs (Small Airway Epithelial Cells) 
immortalized with hTERT were kindly provided by Dr. Tom Hei (48). Primary human 
SAECs were obtained from Lonza. They were cultured in SABM medium supplemented 
with Clonetics SAGM BulletKit (Lonza). All cells were maintained in humidified 
atmosphere at 37 °C, 5% CO2. Cisplatin, etoposide, doxycycline, and 4-
diethylaminobenzaldehyde (DEAB) were purchased from Sigma-Aldrich Corporation 
(St. Louis, MO, USA), and paclitaxel from Acros Organics (Geel, Belgium). 
Plasmids and generation of stable cell lines. SOX9 siRNA (D-059108-01) and 
non-targeting siRNA (D-001810-01), pLKO.1 lentiviral plasmids for SOX9 knockdown 
(#RHS4533-EG6662) were purchased from Dharmacon (Lafayette, CO, USA). An 
empty pLKO.1 vector was used as a control and the virus was produced in HEK293T 
cells (ATCC) as described previously (49). For SOX9 overexpression, SOX9 cDNA from 
pCMV-AC-GFP-SOX9 (Origene, Rockville, MD, USA) was amplified by PCR and 
subcloned into pLUTzeo (a gift from Dr. A. Ivanov, West Virginia University, WV, USA). 
Viral particles were produced as described above, the empty vector was used a control. 
SiRNA transfections (50 nM) were performed on 6-well dishes with Lipofectamine 
RNAiMAX transfection reagent (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s protocol. Cells were lysed or used for subsequent experiments 48 hours 
post-transfection. shRNA and siRNA sequences are listed in the Supplementary table 3. 
Immunoblotting. Western blot analysis was performed as described previously 
(49). Immune complexes were detected by enhanced chemiluminescence in the 




quantified with the Amersham Imager software. Antibodies used in this study are listed 
in the Supplementary table 1. 
Flow cytometry. Cells with high aldehyde dehydrogenase activity were identified 
by staining with the Aldefluor kit (Stem Cell Technologies, Cambridge, MA, USA) 
according to the manufacturer’s instructions. Briefly, for each sample, 3x105 cells were 
incubated in the Aldefluor assay buffer with activated Aldefluor substrate for 45 minutes 
at 37 ºC in the presence or absence of the specific ALDH inhibitor 
diethylaminobenzaldehyde (DEAB). Tubes stained with both the Aldefluor substrate and 
DEAB served as a negative control for each sample. Cells with high ALDH activity 
(ALDHhi) were detected using the BD Fortessa cell analyzer and analyzed with the BD 
FACSDiva software (BD Biosciences, San Jose, CA, USA). The flow cytometry gates 
were set to obtain 0.1% ALDHhi cells in substrate + inhibitor tubes for each sample. All 
experiments were performed at least 3 times. 
Cell proliferation assay. The rate of cell proliferation was measured by seeding 
equal numbers of cells onto 6-well plates in duplicates and counting the cells with the 
Countess automated cell counter (Life Technologies) every 2 days until the plates 
become confluent. 
Cell viability (MTT) assay. Cells were plated onto 96-well plates and allowed to 
recover overnight. Next day, cell culture media were replaced with drug-containing 
media. 10 µl of 5 mg/ml MTT (1-(4,5-dimethyl-2-thiazolyl)-3,5-diphenylformazan) (Tokyo 
Chemical Industry, Portland, OR, USA) were added to each well containing 100 µl of 
cell culture media following 72 hours of drug treatment. After 2 hours of incubation 
under standard cell culture conditions, formazan crystals were dissolved with DMSO 
and absorbance was measured at 570 nm. Cell viability was represented as % of 
vehicle-treated values. 
Colony formation assay. Cells were treated with cisplatin for 2 days under 
standard cell culture conditions and allowed to recover without cisplatin for 4 days. The 
cells (500 cells/well) were then plated onto 6-well plates and cultured under standard 
conditions for 10 days. Colonies were fixed in 100% methanol and stained with 0.5% 
crystal violet solution. Colonies containing over 50 cells were counted using an Olympus 




colony numbers were normalized to those of respective untreated cells. All experiments 
were performed in triplicates. 
Tumor sphere formation assay. 1,000 cells/well were plated onto ultra-low 
attachment 24-well plates (Corning) in 0.8% methylcellulose (MC)-based serum-free 
medium (Stem Cell Technologies, #H4100) supplemented with 20 ng/ml epidermal 
growth factor (BD Biosciences), 10 ng/ml basic fibroblast growth factor (Sigma-Aldrich), 
and 5 mg/ml insulin (Sigma-Aldrich). The number of tumor spheres exceeding 50 µm in 
diameter was quantified under a light microscope after 10 days (H460 cells) or 3 weeks 
(A549 cells) in culture. All experiments were performed in triplicates and repeated at 
least twice, with 5 fields of view analyzed for each replicate. For cisplatin treatments, 
cisplatin was added to the cultures at the plating time and was replenished 2 times a 
week thereafter. 
Chromatin immunoprecipitation (ChIP). ChIP was carried out using the 
SimpleChIP kit with agarose beads (Cell Signaling Technology, Danvers, MA, USA) 
according to the manufacturer’s protocol. Briefly, approximately 1x107 H460 cells were 
used for each immunoprecipitation. Cells were cross-linked with 1% formaldehyde, 
treated with micrococcal nuclease for chromatin digestion, and briefly sonicated to 
break nuclear membranes. 2 µg of anti-SOX9 antibody (AB5535, Millipore, Burlington, 
MA, USA) and negative control normal rabbit IgG (Cell Technologies) were used for 
immunoprecipitation. The amount of total and ChIP DNA was quantified by qPCR after 
reversal of cross-links and DNA purification. Primer sequences are listed in the 
Supplementary table 2. 
Luciferase reporter assay. ALDH1A1 promoter was obtained from SwitchGear 
Genomics (Carlsbad, CA, USA), and was moved from pLightSwitch vector to pBV-luc (a 
gift from Bert Vogelstein, Addgene plasmid # 16539) by restriction enzyme cloning. 
Empty pBV-luc vector was used as a control. The Renilla luciferase vector pIS1 (a gift 
from David Bartel, Addgene plasmid # 12179) served as an internal control for 
transfection efficiency. SOX9 expression in H460 cells was induced by treating the cells 
with 1 µg/ml doxycycline for 5 days before transfection. Cells were transfected on 12-
well plates with pBV-luc or pBV-luc-ALDH1A1 (1 µg/well) and 50 ng of pIS1 using 




Luciferase Reporter Assay (Promega) according to manufacturer’s instructions. 
HEK293 cells were transfected with the luciferase plasmids as above plus pcDNA3.1-
RFP or pcDNA3.1-SOX9. 
RT-qPCR. Total RNA was purified using the RNeasy kit (Qiagen, Germantown 
MD, USA). Reverse transcription was performed with SuperScript III Reverse 
Transcriptase (Life Technologies) using oligo(dT) primers. Quantitative real-time PCR 
was carried out using SYBR Green Master Mix (Applied Biosystems, Foster City, CA) in 
a Step One Plus PCR Cycler (Applied Biosystems). Results were calculated using the 
2−ΔΔCt method; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin 
served as the internal controls. Primer sequences are listed in the Supplementary table 
2. 
Statistical analysis. The data represent means ± SD or SEM as indicated. 
Statistical comparisons were made using two-tailed Student's t test or ANOVA when 
more than two groups were analyzed. Statistical analysis was performed with GraphPad 








The authors wish to thank Dr. Alexey Ivanov for providing pLUTz cloning vector. 
Funding 
This work was supported in part by the National Institutes of Health grants R01-
ES022968 and R01-EB018857. 
Imaging experiments and image analysis were performed in the West Virginia University 
Microscope Imaging Facility, which has been supported by the WVU Cancer Institute 
and the National Institutes of Health grants P20RR016440, P20GM103434 and 
P30RR032138/P30GM103488. 
Flow Cytometry experiments were performed in the West Virginia University Flow 
Cytometry & Single Cell Core Facility, which is supported by the National Institutes of 
Health equipment grant S10OD016165 and the Institutional Development Awards (50) 
from the National Institute of General Medical Sciences of the National Institutes of 
Health under grant numbers P30GM103488 (Cancer CoBRE) and P20GM103434 
(INBRE). 
Competing Interests 
The authors declare that they have no conflict of interests. 
Disclaimer:  
The findings and conclusions in this report are those of the author(s) and do not 
necessarily represent the official position of the National Institute for Occupational 











Figure 1. High SOX9 expression correlates with poor survival in NSCLC patients 
and is induced by cisplatin in lung cancer cells. (A, B) Overall survival in NSCLC 
patients from the TCGA database. Patients with adenocarcinoma (n = 260) (A) and 
squamous cell carcinoma (n = 251) (B) with high SOX9 expression (top 25% expression 
vs. bottom 25%) had a lower overall survival. P values by log-rank (Mantel-Cox) test. 
(C) Western blot analysis of SOX9 expression in normal lung epithelial cells and lung 
cancer cell lines. (D) SOX9 mRNA levels are increased after a 3-day long treatment 
with cisplatin (2 µM for H460, 8 µM for A549 and H1299 cells). Data are mean ± SD, 
Representative of 3 independent experiments, p < 0.0001 by one-way ANOVA; Tukey's 
multiple comparison test. (E) H460 cells became resistant to cisplatin after a 3-day 
exposure to 2 µM cisplatin (IC50 4.3 µM vs. 1.4 µM). Cisplatin resistant cells were 
treated with various cisplatin concentrations for 72 hours and cell viability was assessed 
by MTT assay. Representative of 3 independent experiments, 5 technical replicates 
each. Data are mean ± SD, p < 0.0001 by two-way repeated measures ANOVA. (F) 
Representative Western blot showing SOX9 upregulation in H460 cells in response to 









Figure 2. SOX9 overexpression promotes chemoresistance in NSCLC cells. (A) 
Dose-response curves of H460 and A549 cells transfected with control and SOX9 
siRNA. Cell viability was evaluated by MTT assay following a 3-day cisplatin treatment. 
Representative of 3 independent experiments, 4 technical replicates in each. Data are 
mean ± SD. (B) Dose-response curve of empty vector and SOX9 overexpressing H460 
cells following a 3-day cisplatin treatment. SOX9 expression was induced by 
doxycycline treatment 5 days prior to the experiment. Representative of 5 independent 
experiments, 5 technical replicates in each. Data are mean ± SD. (C) Same as in (B) in 
A549 cells. (D) Colony formation assay in vector control and SOX9 knockdown H460 
cells. Cells were treated with 4 µM of cisplatin for 2 days, off cisplatin for 4 days, and 
allowed to form colonies for 10 days. The cells were then fixed, stained with crystal 
violet, and visualized by light microscopy. Data are mean ± SD, scale bar = 3 mm, n = 2 
biological replicates. p = 0.0021 by one-way ANOVA; Tukey's multiple comparison test. 
(E) Same as in (D) with SOX9 overexpressing cells exposed to 2 µM of cisplatin. n = 3 







Figure 3. SOX9 promotes cancer stem-like properties. (A) Tumor sphere formation 
in H460 cells expressing an empty vector or each of the two shRNAs against SOX9, n = 
3 biological replicates. Data are mean ± SD; p < 0.0001 by one-way ANOVA; Tukey's 
multiple comparison test. Scale bar = 500 µm. (B, C) Same as in (A) with the empty 
vector and SOX9 overexpressing cells, and secondary tumor spheres formed by the 
cells from primary spheres (C). Means ± SD are shown; p = 0.005 for primary spheres, 
p = 0.012 for secondary spheres by unpaired two-tailed t test, n = 3 biological replicates. 
(D) Decreased mRNA expression of stem-cell markers in SOX9 knockdown cells (sh-1, 
sh-2) vs. control vector. The data are presented as mean ± SD, * p < 0.05 comparing to 
vector, two-way ANOVA followed by Bonferroni posttests. (E) As in (B) plus cells were 
exposed to 0.25 µM of cisplatin for the duration of the experiment, p = 0.043 by 
unpaired two-tailed t test, n = 3 biological replicates. All experiments were repeated at 









Figure 4. ALDH1A1 is a downstream target of SOX9. (A) Left - representative 
Western blot analysis of SOX9 and ALDH1A1 expression in SOX9 knockdown (sh 1, 2, 
3) and empty vector H460 cells. Right – ALDH1A1 mRNA levels in same cells. Data are 
mean ± SEM, n = 3, p < 0.0001 by one-way ANOVA; Tukey's multiple comparison test. 
(B) Representative Western blot showing an increased expression of ALDH1A1 in 
SOX9 overexpressing H460 cells, n = 6 independent experiments. (C) SOX9 
overexpression induced ALDH1A1 mRNA levels in H460 cells. Data are mean ± SD, n = 
7 independent experiments, p = 0.004 by paired t test. (D) Analysis of ALDH activity by 
Aldefluor assay in empty vector and SOX9 overexpressing H460 cells. Left – a 
representative flow cytometry gating for Aldefluor assay. Right – % of cells with high 
ALDH activity, n = 3 independent experiments, 2 biological replicates each. Data are 
mean ± SD, p < 0.001, paired two-tailed t-test. DEAB - N, N-diethylaminobenzaldehyde, 
ALDH inhibitor, used to set up background fluorescence level for all flow cytometry 
experiments. (E) RT-qPCR analysis of 19 ALDH isoforms in SOX9 knockdown (sh-1, -2, 
-3) and empty vector H460 cells. Data are mean ± SD, * p < 0.05 comparing to vector, 






Figure 5. SOX9 promotes chemoresistance through ALDH1A1. (A) Representative 
western blot analysis of SOX9 and ALDH1A1 expression in H460 cells after exposure to 
2 µM cisplatin. (B) Treatment with ALDH inhibitor DEAB enhances sensitivity to 
cisplatin. H460 cells were pretreated with 200 µM DEAB or DMSO for 24 h, followed by 
cisplatin treatment and analyzed for cell viability after 3 days by MTT assay. DEAB 
decreased IC50 of H460 cells 2.5 ± 0.3 folds, n = 5 independent experiments, p = 0.0110 
by paired t test. (C) ALDH inhibitor DEAB reverses the effect of SOX9 overexpression in 
H460 cells. Cisplatin dose-response curve evaluated by MTT assay. Data are mean ± 
SD, two-way ANOVA with Bonferroni posttests. All experiments were repeated at least 






Figure 6. ALDH1A1 is regulated by SOX9 at the transcriptional level. (A) SOX9 
overexpression induced by doxycycline for the indicated length of time stimulates 
ALDH1A1 expression. The blots shown are representative of two independent 
experiments. (B) Schematic image of the ALDH1A1 promoter and locations of primer 
sets used in (C). (C) SOX9 binding is enriched at the ALDH1A1 promoter. SOX9 ChIP 
results were analyzed by qPCR with primers specific to the indicated DNA regions. IgG 
was used as a negative IP control. Primers to COL2A1 served as negative and positive 
controls for ChIP. Data are mean ± SD, ** - p < 0.01, two-way ANOVA with Bonferroni 
posttests. ns – not significant. (D) Luciferase reporter assay with the ALDH1A1 
promoter. H460 cells stably expressing empty vector or SOX9 were transfected with 
ALDH1A1 luciferase reporter plasmid. Luciferase activity was analyzed 48 hours 
posttransfection and normalized to Renilla luciferase signal. p = 0.028 by unpaired two-
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Supplementary Figure 1. SOX9 expression levels correlate with drug sensitivity in 
NSCLC cells. (A) A549 cells exposed to 8µM cisplatin for 3 days become less sensitive 
to the chemodrug (IC50 27.8 µM vs. 6.0 µM). Mean ± SD, the experiment was repeated 
3 times. Cell viability was measured by MTT assay. (B) SOX9 knockdown renders H460 
cells sensitive to cisplatin. Results are shown as mean ± SD. A representative western 
blot image demonstrates SOX9 knockdown levels generated by 2 shRNAs against 
SOX9 (sh-1 and sh-2) comparing to vector control. (C) Same as in B in A549 cells. (D) 
SOX9 overexpression in H460 cells induces resistance to etoposide. Results are mean 
± SD, the experiment was repeated 3 times. A representative western blot image 
demonstrates levels of SOX9 overexpression. (E) SOX9 overexpression renders A549 
cells resistant to etoposide and paclitaxel (p = 0.0036). Results are shown as mean ± 
SEM. Right – representative western blot analysis of SOX9 protein levels in SOX9 
overexpressing A549 cells and vector control cells. *** - p < 0.0001 by two-way 






Supplementary Figure 2. SOX9 expression correlates with drug sensitivity in 3-D 
conditions in A549 cells. (A) Representative pictures of tumor spheres formed by 
A549 cells expressing the empty vector or shRNAs against SOX9 (sh-1, sh-2) under 
standard conditions or after cisplatin (1.5 µM) treatment. Scale bar – 300 µm. Right – 
quantification of spheroids after treatment with cisplatin. p = 0.0042 by one-way ANOVA 
followed by Tukey's multiple comparison test. Bars are mean ± SD, n = 3. (B) 
Representative pictures of tumor spheres formed by A549 cells expressing the empty 
vector or SOX9 under standard conditions or after cisplatin (1.0 µM) treatment. Scale 
bar – 300 µm. Bars are means ± SD, n = 3; p = 0.0106 by unpaired two-tailed t test. (C) 
SOX9 overexpression slows down cell proliferation in H460 and A549 cells. Proliferation 
rate of the indicated cells was analyzed by counting the cells every 2 days, n = 3 
biological replicates. p = 0.011 for H460, p = 0.0068 for A549 cells by two-way repeated 






Supplementary Figure 3. (A) Treatment with ALDH inhibitor DEAB enhances 
sensitivity to cisplatin. H460 cells were pretreated with 200 µM DEAB or DMSO for 24 h, 
followed by cisplatin treatment and analyzed for cell viability after 2 days by MTT assay. 
Means ± SD are shown, p < 0.0001 by two-way repeated measures ANOVA followed by 
Bonferroni posttests. (B) Real-time PCR analysis of mRNA levels of indicated stem cell 
markers in A549 cells expressing the empty vector or shRNAs against SOX9 (sh-1, sh-
2). Means ± SD are shown, p < 0.05 by two-way ANOVA followed by Bonferroni 
posttests. (C) SOX9 induces ALDH1A1 luciferase reporter activity in HEK293 cells. 
Cells were transfected with the indicated constructs and luciferase activity was 
measured 48h posttransfection. Bars are mean ± SEM, p = 0.0044 by unpaired two-






Supplementary Table 1. List of antibodies used in this study. 
Name Company Catalog # 
SOX9 EMD Millipore AB5535 
ALDH1A1 EMD Millipore MABN838 
β-actin Sigma-Aldrich A5441 
GAPDH EMD Millipore CB1001 
anti-rabbit-HRP Jackson ImmunoResearch 711-035-152 
anti-mouse-HRP Jackson ImmunoResearch 715-035-151 
 
Supplementary Table 2. Oligonucleotides for real-time quantitative PCR analysis. 
Name Forward (5' to 3') Reverse (5' to 3') 
ALDH1A1 AGTGTGGGTGAATTGCTATGG TGTGACTGTTTTGACCTCTGT 
ALDH1A2 AAGATGTCTGGAAATGGGAGAG GGGATCTTTACTGTCACCGTC 
ALDH1A3 CTTCTGCCTTAGAGTCTGGAAC TGCTACGTGGACAAGAACTG 
ALDH1B1 CCCAAGCGTGATCCTGAAC ATGTCTGGGTTCAGAATGGG 
ALDH1L1 GTACAACCGCTTCCTCTTCC TTGATCTTGGCTGTCTCCTTC 
ALDH1L2  ACGACACTATCAACCCAACAG TCTTCCCCATTCACCGTTTTC 
ALDH2 ATGAGTTTGTGGAGCGGAG TTCCCCGTGTTGATGTAGC 
ALDH3A1 CCTTAAATACGTCCCCTCTTGG TCGCTGATCTTGCTCATGG 
ALDH3A2  TGTTGCTCACTTTCCTGGG GCTGGGTTTTGAAATCTGGTG 
ALDH3B1  AGCCATCGGAGATTAGCAAG AAGATGTAGTCGAACCTGTGC 
ALDH3B2  TTCCTTCAAGAAAACAAGCAGC CAGGTTCTTGAGAGCGTAGTC 
ALDH4A1  CCGCTTCTAACCCGAGATG CCTGCGTGAAGGCTAAGAC 
ALDH5A1  TGGCACCAGTTATCAAGTTCG AACCATGCCCACTTCCAG 
ALDH6A1  TGAAGGAGATGTATTTCGAGGC GAGGCAGACGGTAGGAATAAAG 
ALDH7A1 AGTATGCGTGGCTGAAAGAG CCTGTCGGACTCTTGCTATTG 
ALDH8A1 AAAGTCGGCATTCCCTCTG CAACTTATCCACTCCCTCACC 
ALDH9A1  ACAACTATAACGTCAGCCCAG CACATCACCCATCTCCACAC 
ALDH16A1 GCTGGAGCTGGGCTATG GCCGCAGATACTCATACAGC 
ALDH18A1 ATCTGGCTGATCTGTTGACG GGCTGTTCAATTTGGATGTGG 
β-actin ACCTTCTACAATGAGCTGCG CCTGGATAGCAACGTACATGG 







Supplementary Table 3. siRNA and shRNA sequences. 
Gene Name Sequence Dharmacon catalog # 
Control siCtl UGGUUUACAUGUCGACUAA D-001810-01 
SOX9 siSOX9 GAACGCACATCAAGACGGA D-059108-01 
SOX9 sh-1 TATACAGAAATTGAAGGATGC RHS3979-201751501 
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Engineered nanomaterials hold great promise for future development of innovative 
products, but their adverse health effects are a major concern. Recent studies have 
indicated that certain nanomaterials, including carbon nanotubes (CNTs), may be 
carcinogenic. However, the underlying mechanisms behind their potential malignant 
properties remain largely unknown. In this study, we investigated the potential role of 
SOX9, a stem cell associated transcription factor, in neoplastic transformation of human 
lung epithelial cells after chronic exposure to low-dose single-walled carbon nanotubes 
(SWCNTs). We found that SOX9 is upregulated in chronic SWCNT-exposed cells, 
which is consistent with their abilities to induce tumor formation and metastasis in vivo. 
We therefore hypothesized that SOX9 overexpression may be responsible for the 
neoplastic-like phenotype observed in our model. Indeed, SOX9 knockdown inhibited 
anchorage-independent cell growth in vitro and lung colonization in vivo in a mouse 
xenograft model. SOX9 depletion also suppressed the formation of cancer stem-like 
cells (CSCs), as determined by tumor sphere formation and aldehyde dehydrogenase 
(ALDH) activity (Aldefluor) assays. Furthermore, SOX9 knockdown suppressed tumor 
metastasis and the expression of the stem cell marker ALDH1A1. Taken together, our 
findings provide a mechanistic insight into SWCNT-induced carcinogenesis and the role 







Engineered nanomaterials have increasingly been used for various applications, 
but their long-term health effects are largely unknown. Carbon nanotubes (CNTs) are 
one of the most commonly used engineered nanomaterials due to their unique 
properties such as light weight, high tensile strength, and electrical conductivity1,2. 
However, CNTs have some negative properties as well, such as a high aspect ratio and 
biopersistence; therefore, questions about their potential carcinogenicity have been 
raised3,4. Previous animal studies have shown that pulmonary exposure to single-walled 
carbon nanotubes (SWCNTs) induces inflammation, granulomas, and fibrosis5,6, 
conditions that have been associated with an increased risk of lung cancer7,8. In fact, 
some CNTs can induce or promote tumor formation in animals3,9-12. Furthermore, one 
type of CNTs, multi-walled carbon nanotubes (MWCNTs) Mitsui-7, was classified as 
possibly carcinogenic to humans by the International Agency for Research on Cancer 
(IARC)13, while in vitro data on other CNT types were concluded insufficient to be 
extrapolated to humans.  
We previously reported that long-term, low-dose exposure of human lung 
epithelial cells to SWCNTs and MWCNTs results in neoplastic-like transformation14,15. 
Long-term treatment with CNTs was applied to mimic gradual cellular transformation 
during cancer development, a process that may require a prolonged exposure to 
carcinogens16-18. We also reported that chronically SWCNT-exposed cells contain a 
highly invasive and tumorigenic stem-like cell subpopulation19,20. However, detailed 
information about the underlying mechanisms remains unknown.  
Increasing amounts of evidence suggest that cancer stem cells or stem-like cells 
(CSCs), also called tumor initiating cells, are the main driving force behind tumor 
formation and metastasis21,22. CSCs and regular stem cells share many properties, 
including self-renewal capacity, potency for differentiation, and resistance to apoptosis. 
More importantly, CSCs are typically resistant to chemotherapy and eventually give rise 
to recurrent tumors22,23. 
Many stem cell regulatory proteins are now being recognized as oncogenes 




is a member of the SOX family of transcription factors, which play critical roles in 
embryonic development, lineage commitment, and stem cell maintenance24. Notably, 
SOX9 is involved in lung branching morphogenesis25, and its expression is elevated in 
many types of cancer, including lung, skin, brain, and pancreatic cancers26. In non-small 
cell lung cancer (NSCLC), the most common type of lung cancer, SOX9 expression 
highly correlates with the disease progression and poor patient survival27,28. 
Accumulating evidence also suggests that SOX9 may regulate CSCs29-32. However, 
detailed mechanisms have yet to be elucidated. Furthermore, it is not known whether 
SOX9 plays a role in SWCNT-induced carcinogenesis and CSC formation.  
In this study, we demonstrated that chronically SWCNT-exposed human lung 
cells display high levels of SOX9 expression and contain a distinct CSC subpopulation. 
We hypothesized that SOX9 overexpression may be responsible for the malignant 
phenotype observed in these cells. Consequently, we evaluated the effects of SOX9 
expression on the tumorigenicity, invasiveness, and stemness of SWCNT-transformed 







Exposure to carbon nanotubes induces cell transformation 
To test the potential role of SOX9 in SWCNT-induced oncogenesis, human 
bronchial epithelial Beas-2B cells were continuously exposed to occupationally relevant 
concentrations (0.02 μg/cm2) of SWCNTs for a period of 6 months, as previously 
described14,15,19. Physicochemical properties of SWCNTs used in this study are 
summarized in Table 1. Potential carcinogenic properties and SOX9 expression were 
then evaluated in vitro and in vivo. Analysis of anchorage-independent cell growth, a 
hallmark of cancer33,34, revealed that the SWCNT-treated cells (termed BSW) formed 5-
fold more colonies when compared to passage-matched control (B2B) cells (Fig. 1a). To 
evaluate the tumorigenic potential of BSW cells in vivo, these cells and the control B2B 
cells were genetically labeled with luciferase and injected subcutaneously into the flanks 
of NOD/SCID gamma mice. Tumor formation was examined over a period of 4 weeks 
by external caliper measurements and by bioluminescence imaging. Unlike control cells, 
BSW cells formed rapidly growing tumors (Fig. 1b, c). Moreover, ex vivo analysis at the 
end of the experiments showed spontaneous metastasis of the BSW cells to the mouse 
lungs and liver (Fig. 1d, e, f and Supplementary Fig. S1). These results indicate that 
SWCNT-transformed cells possess tumorigenic and metastatic properties. 
 
SOX9 overexpression regulates malignant properties of BSW cells 
Cancer stem cells (CSCs) are considered to be the main source of cancer 
metastasis, chemoresistance, and tumor recurrence21. Previous studies have shown 
that SWCNT-exposed cells contain a CSC-like subpopulation identical to CSCs 
reported in lung cancer19,35. This cell population is characterized by the expression of 
stem cell markers, self-renewal ability, and more importantly by chemoresistance and 
high tumorigenic potential19,20. In this study, we examined the molecular mechanisms of 
CSC regulation to identify possible biomarkers and drug targets for CNT-related 
malignancies. SOX9, a stem cell transcription factor, has recently been implicated in 
CSC regulation26,29 and is overexpressed in non-small cell lung cancer (NSCLC)27,32. 




SWCNT-exposed cells by controlling CSCs. Indeed, BSW cells express a high level of 
SOX9 protein when compared to passage-matched control cells (Fig. 2a). Furthermore, 
immunostaining analysis revealed that lungs of all mice in the BSW group contain SOX9 
overexpressing micrometastases (Fig. 2b). Immunofluorescent staining for CSC 
markers in control and SWCNT-exposed cells demonstrated that CSC markers are 
overexpressed in BSW cells and that the CSCs are the cells that have elevated SOX9 
expression (Supplementary Fig. S2). 
To test our hypothesis, SOX9 expression in BSW cells was stably knocked down 
by shRNAs (Fig. 3a). The knockdown cells (shSOX9) exhibited a slower rate of 
proliferation (Fig. 3b) and formed substantially fewer colonies in the soft agar assay 
when compared to vector control cells (Fig. 3c, d). These results suggest that SOX9 
depletion alleviates the survival of cells in matrix depleted conditions and potentially 
decreases their metastatic potential. In vitro migration and invasion assays further 
demonstrated a marked reduction in cell motility following SOX9 knockdown (Fig. 4). 
We also used an established NSCLC cell line H460 to compare the results of SOX9 
downregulation in BSW cells to those in lung cancer cells. SOX9 knockdown also 
attenuated colony formation and decreased the proliferation rate of H460 cells 
(Supplementary Fig. S3), which is consistent with previous reports28,32. Taken together, 
our results support the critical role of SOX9 overexpression in the malignant phenotype 
of SWCNT-exposed cells. Specifically, SOX9 knockdown reduced cell proliferation, 
colony formation, migration, and invasion - properties that all are considered as 
hallmarks of cancer33. 
 
SOX9 regulates SWCNT-induced cancer stem cells 
The ability for self-renewal is a key characteristic of stem cells36,37. The tumor 
sphere formation assay has frequently been used as a functional in vitro test to evaluate 
the self-renewal ability of adult stem cells and cancer stem cells38,39. To evaluate the 
sphere forming capability of SWCNT-transformed cells and its regulation by SOX9, 
1,000 control and shSOX9 cells were cultured under non-adherent conditions in serum-




diameter was quantified. We found that SOX9 knockdown substantially inhibited sphere 
formation (Fig. 5a), suggesting that SOX9 positively regulates stem cells in our model.  
Next, we evaluated the expression and activity of the common cancer stem 
marker ALDH, which is highly active in cancer stem cells and is frequently associated 
with poor clinical outcomes23,40,41. The Aldefluor assay was used to quantify ALDH 
activity in BSW and BSW-shSOX9 cells. The activated Aldefluor reagent is a cell-
permeable fluorescent substrate for ALDH that accumulates inside cells after interaction 
with ALDH and can be subsequently detected using flow cytometry. 
Diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, was used to evaluate 
background fluorescence and set up gates for flow cytometry. We found that ALDH 
activity was substantially decreased in SOX9 knockdown cells, as indicated by a 
reduced number of cells exhibiting high ALDH activity (ALDHhi cells) (Fig. 5b, c). 
Consistent with the pattern of ALDH activity, expression levels of ALDH1A1, one of the 
main CSC-associated ALDH isoforms42,43, were dramatically reduced following SOX9 
knockdown (Fig. 5d). ALDH1A1 expression was also depleted in H460-shSOX9 cells 
(Supplementary Fig. S3), indicating that a correlation between SOX9 and ALDH 
expression is not limited to one specific cell system. These results suggest that SOX9 
controls CSCs in BSW cells and possibly other cancer cell types through ALDH1A1. 
 
SOX9 knockdown attenuates BSW metastasis in vivo 
We next evaluated whether SOX9 depletion affects the metastatic potential of 
BSW cells in vivo. Luciferase-labeled BSW and BSW-shSOX9 cells were intravenously 
injected into mice followed by weekly bioluminescence imaging. At the end of the 
experiment, mice were euthanized; their internal organs (brain, liver, spleen, pancreas, 
kidneys and lungs) were removed and imaged to evaluate metastatic lesions. Figure 6a 
shows representative whole-body bioluminescence images of mice bearing either the 
control or shSOX9 cells. Importantly, lung colonization by shSOX9 cells was 
dramatically decreased when compared to control cells (Fig. 6b). This was also 
confirmed by ex vivo lung imaging (Fig. 6c) and by histological analysis (Fig. 6d). The 
luminescent signals from distant metastases in the liver and brain also decreased (Fig. 




pancreas in the control but not in the shSOX9 animals (data not shown). Our findings 
indicate a significant role of SOX9 in the regulation of the metastatic properties of 
malignantly transformed BSW cells. 
 
SOX9 overexpression in normal Beas-2B cells induces stem cell-like properties 
We next overexpressed SOX9 in passage-matched control (B2B) cells to test 
whether this would be sufficient to recapitulate the phenotype of BSW cells. Of note, we 
achieved a maximum 5-fold increase of SOX9 expression (Fig. 7a), while BSW cells 
have on average a 15-fold increase in SOX9 expression in comparison to Beas-2B cells 
(Fig. 2a). Nevertheless, a 5-fold SOX9 overexpression in Beas-2B cells was sufficient to 
promote tumor sphere formation (Fig. 7b, c). Note that these cells normally form a small 
number of loose cell aggregates under low-attachment conditions, while SOX9 
overexpression triggered the appearance of typical, round tumor spheres. Furthermore, 
mRNA levels of main NSCLC-associated isoforms ALDH1A1 and ALDH1A344 as well as 
ALDH activity were upregulated by SOX9 (Fig. 7d, e). We also evaluated changes in the 
expression levels of stem cell related proteins in response to SOX9 overexpression. We 
observed an increased expression of CD133, a marker of lung CSCs45, and embryonic 
stem cell factors Nanog, SOX2 and Oct4, although the increase was not statistically 
significant in the case of Oct4 (Fig. 7f). Together, these results support the regulatory 







In this study, we demonstrated that lung epithelial cells chronically exposed to 
SWCNTs may undergo malignant transformation and gain metastatic properties. These 
cells displayed traits typically characteristic of cancer cells, including anchorage-
independent growth and in vivo tumor formation, supporting the previously published 
work14,19. In addition, the metastatic potential of SWCNT-exposed cells was 
demonstrated for the first time. We observed that BSW cells can metastasize in both 
subcutaneous (Fig. 1) and tail vein mouse models (Fig. 6). We showed for the first time 
that SOX9 is a critical player in SWCNT-induced carcinogenesis, and that SOX9 
depletion significantly reduces metastatic potential both in vitro (Fig. 4) and in vivo (Fig. 
6).  
Cancer stem cells (CSCs) have been considered the main source of cancer 
initiation, dissemination, and recurrence based on their ability for self-renewal, drug- 
and apoptosis resistance. Furthermore, multiple studies have illustrated that tumor 
initiating cells share some characteristics with regular stem cells and express stem cell 
markers. Thus, it is not surprising that many proteins that are involved in embryonic 
development, such as the SOX family of proteins, appear to be CSC drivers. Our study 
demonstrated a high level of SOX9 expression in aggressive SWCNT-exposed cells, 
consistent with recent reports of SOX9 up-regulation in multiple cancer types26. 
However, the functional role of SOX9 in transformed cells required further investigation. 
We hypothesized that the elevated SOX9 expression in cancer cells and SWCNT-
exposed cells may induce CSC formation, which in turn could drive tumor formation and 
metastasis. Indeed, we found that SOX9 knockdown strongly inhibited tumor sphere 
formation and anchorage-independent growth (Fig. 5a, Fig. 3c, d). Bioluminescence 
signals from mouse lungs in the tail vein model clearly demonstrated that SOX9 
knockdown decreases lung colonization (Fig. 6). Together, these results suggest that 
SOX9 regulates cancer cell survival, consistent with our previous work in lung cancer32. 
We tested how SOX9 affects CSC markers to further evaluate our hypothesis. 
Elevated activity of ALDH, an enzyme with a variety of functions including detoxification, 




CSCs23,40,41. We observed a substantial decrease in ALDH activity following SOX9 
knockdown (Fig. 5d, c), suggesting that ALDH may be a potential downstream target of 
SOX9. Likewise, the expression of ALDH1A1, an ALDH isoform most commonly 
associated with the CSC activity23,40,42, was dramatically reduced in both BSW and 
H460 knockdown cells (Fig. 5d, Supplementary Fig. S3). Notably, ALDH serves not only 
as a stem cell marker, but also governs stem cell differentiation46,47 by producing 
retinoic acid48. To further explore the potential relationship between ALDH and SOX9, 
we overexpressed SOX9 in control Beas-2B cells. We observed an increase in tumor 
sphere formation (Fig. 7b, c), which is consistent with the knockdown experiments. 
Likewise, mRNA levels of the reported to be overexpressed in NSCLC ALDH isoforms 
ALDH1A1 and ALDH1A344 were elevated, validating our findings in SOX9 knockdown 
cells. We also observed an increased expression of stem cell makers CD133, Nanog 
and SOX2 (Fig. 7 f), suggesting that SOX9 overexpression renders cells less 
differentiated. Collectively, our observations strongly support the positive regulatory role 
of SOX9 in CSC formation, consistent with other studies in pancreatic, esophageal, and 
colorectal cancers30,49,50. To our knowledge, the present study demonstrates the 
mechanistic link between SOX9 and ALDH expression for the first time. This provides a 
key mechanism underlying CSC induction by SOX9, while the exact mode of ALDH 
upregulation remains a subject for further investigation. 
A limitation of this study is that the results were largely derived from one cell 
model (Beas-2B cells) and one type of CNTs. However, our group observed a similar 
neoplastic-like transformation in several other models and with different types of CNTs. 
For examples, MWCNTs have recently been shown to induce neoplastic transformation 
of primary human small airway epithelial cells51. Both SWCNTs and MWCNTs similarly 
induced such transformation in hTERT-immortalized human small airway epithelial cells 
after a long-term exposure15. The induction of fibroblast stem-like cells and ALDH1A1 
expression was also reported in primary human lung fibroblasts exposed to SWCNTs or 
MWCNTs51. Furthermore, co-culture of these activated fibroblasts with lung cancer cells 
promoted CSC-related properties and tumor formation by cancer cells52. Of note, animal 
experiments in the current study were conducted in immunodeficient mice, and 




studies using immunocompetent mice and rats consistently indicate the tumorigenic 
potential of SWCNTs and MWCNTs9-12. While SOX9 is implicated as a key regulator of 
SWCNT-induced carcinogenesis in this report, other regulatory mechanisms are likely 
to be involved due to the complexity of carcinogenic process. For example, Shvedova et 
al. showed that inhalation or aspiration of SWCNTs caused lung inflammation and 
fibrosis along with K-ras mutation in immunocompetent mice53. Since K-ras is a known 
oncogene, whose mutational activation is frequently associated with an increased risk of 
lung cancer, it is quite possible that such mutation may be involved in SWCNT-induced 
carcinogenesis, although this has not been demonstrated yet. In addition, several 
studies evaluating CNT carcinogenicity via whole transcriptome arrays have identified 
cancer signatures and known cancer prognostic markers in exposed mouse lung 
tissues54,55. Some of the identified genes such as caveolin-1 and Bcl-2 have already 
been implicated in CNT-induced carcinogenesis20,56 and may be responsible for the 
early neoplastic transformation induced by SWCNTs. 
Lung cancer is a progressive disease commonly associated with a long-term 
exposure to carcinogens. However, prolonged exposure studies to nanomaterials are 
lacking and are greatly needed for risk assessment and for safe-by-design strategies. 
Our results suggest that long-term exposure to SWCNTs could transform normal 
epithelial cells into metastatic tumor cells. Although multiple mechanisms and signaling 
pathways are likely to be involved in the transformation process, we report here the 
critical role of SOX9 in the transformation through CSC-related mechanisms. Given that 
CSCs may be involved in cancer initiation steps, we suggest that SOX9 may be used as 
an early biomarker for SWCNT-induced carcinogenesis. It remains to be elucidated 
whether SOX9 up-regulation and its contribution to malignancies are specific to 
SWCNTs or could be extrapolated to other CNTs. Such information will aid in the design 






Cell culture and exposure to SWCNTs. Immortalized human bronchial 
epithelial Beas-2B cells were obtained from the American Type Culture Collection 
(ATCC). Cells were cultured in advanced Dulbecco’s modified Eagle medium (DMEM) 
(Life Technologies) supplemented with 1% fetal bovine serum (FBS, Atlanta 
Biologicals), 2 mM L-glutamine, 20 mM HEPES, 100 units/mL penicillin and 100 μg/mL 
streptomycin in 5% CO2 at 37 °C. This cell model has been reported to be an 
appropriate model for in vitro lung carcinogenesis studies57. The cells were exposed to 
well-characterized single-walled CNTs (SWCNTs), as previously described14,19. Briefly, 
SWCNTs (Carbon Nanotechnology (CNI)) were purified by acid treatment to remove 
metal contaminates. Particle characterization studies were performed at NIOSH 
research facilities, and the results are summarized in Table 1. Particles were treated 
with acetone and placed in an ultrasonic bath at room temperature for 24 h. The 
dispersed CNTs were then filtered from the solution using a 20 μm nylon mesh screen 
followed by a 0.2 μm polytetrafluoroethylene (PTFE) filter. After filter collection, the 
dispersed CNTs were washed thoroughly with distilled water to remove acetone. The 
filter was dried overnight in vacuum and weighed to determine the quantity of SWCNTs. 
The particles were suspended in phosphate-buffered saline (PBS) by brief sonication 
and added to the cells every 3-4 days when changing the culture medium. Subconfluent 
cultures of Beas-2B cells were continuously exposed to a low-dose, occupationally 
relevant concentration (0.02 μg/cm2 or 0.1 μg/mL) of SWCNTs in culture for 6 months 
and passaged weekly. Cells were rinsed with PBS prior to culture medium changes and 
cell passaging to reduce potential SWCNT bioaccumulation over the exposure period.  
The dose of SWCNTs used in this study was calculated based on reported 
effects of in vivo MWCNT exposure, normalized to mouse alveolar surface area. The 
lowest dose, which induced a biological response in vivo, was 10 μg/mouse lung (0.5 
mg/kg body weight)6. Dividing this dose by the average mouse alveolar surface area 
(~500 cm2) gives the in vitro surface area dose of 0.02 μg/cm2, which is roughly 
equivalent to a human lung burden for 8 hours/day over a month at 400 μg/m3 (high 




level in U.S. facilities)59. The cells were cultured in normal medium without SWCNTs for 
at least ten passages prior to further experiments Control cells were cultured for the 
same period of time in the above described culture medium. H460 (NCI-H460) cells 
were purchased from the ATCC and were passaged less than 20 times. H460 cells 
were maintained in RPMI medium (Corning) supplemented with 10% FBS, 100 units/mL 
penicillin, and 100 μg/mL streptomycin.  
Plasmids and generation of stable cell lines. pLKO.1 lentiviral plasmids for 
SOX9 knockdown generation were purchased from GE Healthcare (#RHS4533-
EG6662). An empty vector was used as a control, and the virus was produced in 
HEK293T cells (ATCC). Briefly, HEK293T cells were co-transfected with the shRNA 
containing pLKO.1 plasmids or empty pLKO.1 vector, pCMV-VSV-G envelope, and 
psPAX2 packaging plasmids (Addgene #8454, 12260) in the presence of FuGene 6 
transfection reagent (Promega). The medium containing viral particles was collected at 
24, 36, and 48 hours post-transfection, pooled, and used to infect SWCNT-exposed 
(BSW) cells in the presence of hexadimethrine bromide (Sigma-Aldrich) at a final 
concentration of 5 μg/mL. After infection, cells were selected with 1 μg/mL of puromycin 
(Life Technologies). For SOX9 overexpression, SOX9 cDNA from pCMV-AC-GFP-
SOX9 (Origene) was amplified by PCR introducing BamHI/SalI restriction sites and was 
subcloned into pLenti CMV GFP Zeo (Addgene #17449), replacing GFP. pLenti CMV 
GFP Zeo vector was used as a control. For flow cytometry experiments (Aldefluor 
assay), control vector with RFP instead of GFP was used. Viral particles were produced 
as described above.  
Immunoblotting. Cells were lysed in a non-reducing loading buffer containing 63 
mM Tris-HCl pH 6.8, 10% glycerol, and 2% sodium dodecyl sulfate (SDS). Protein 
concentrations were quantified using the Pierce BCA protein assay kit (Thermo-
Scientific). Proteins (40 μg) were resolved under denaturing conditions by 7.5-12% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto PVDF 
membranes (EMD Millipore). Membranes were blocked in 5% non-fat milk in TBS-T 
buffer (25 mM Tris-HCl, pH 7.4, 125 mM NaCl, and 0.1% Tween 20) for 1 hour, washed 
3 times for 5 minutes with TBS-T buffer, and incubated with appropriate primary 




buffer; membranes were then incubated with appropriate HRP-conjugated secondary 
antibodies (Jackson Immunoresearch), diluted in TBS-T for 1 hour at room temperature. 
Immune complexes were detected by enhanced chemiluminescence (Pierce ECL, 
Thermo-Scientific; Immobilon HRP Substrate, Millipore) and quantified with the Image 
Studio Lite program (Li-COR Biosciences). Antibodies used in this study are listed in the 
Supplementary Table 1. Full length unprocessed blot images are provided in the 
Supplementary Materials. 
Flow cytometry. The ALDHhi population (cells with high aldehyde 
dehydrogenase activity) was identified by staining cells with the Aldefluor kit (Stem Cell 
Technologies), according to the manufacturer’s instructions. Briefly, for each sample, 
3x105 cells were incubated in the Aldefluor assay buffer with the activated Aldefluor 
substrate for 45 minutes at 37 ºC in the presence or absence of the specific ALDH 
inhibitor diethylaminobenzaldehyde (DEAB). Tubes stained with both the Aldefluor 
substrate and DEAB served as a negative control for each sample. ALDH converts 
Aldefluor substrate into a fluorescent product, and cells with high ALDH activity (ALDHhi) 
were detected by BD Fortessa cell analyzer (BD Biosciences). The flow cytometry gates 
were set to obtain 0.1% ALDHhi cells in substrate + inhibitor tubes for each sample. All 
experiments were performed at least 3 times. 
Soft agar colony formation assay. Cells were suspended in a soft agar 
medium containing 0.33% Difco agar (BD Biosciences) in 2x EMEM medium (Lonza) 
supplemented with L-glutamine, antibiotics and 15% FBS, and plated onto 6-well plates 
over a layer of 0.5% soft agar medium. Cells were cultured under standard cell culture 
conditions and were fed with 0.2 mL of the regular medium twice a week. Plates were 
observed under a light microscope after 2 weeks, and colonies exceeding 50 μm in 
diameter were scored. Experiments were performed in triplicates; at least 5 fields of 
view for each replicate were evaluated. 
Migration and invasion assays. Cells were seeded in the upper chamber of 
Transwell matrigel coated (invasion) or control inserts (migration) with 8 µm pores 
(Corning) in serum-free medium and were allowed to migrate or invade toward the 
serum-containing bottom chamber for 15 hours. Cells were subsequently removed from 




stained with crystal violet. Experiments were performed in at least duplicates, 5 random 
fields were photographed under a light microscope for each replicate.  
Cell proliferation assay. The rate of cell proliferation was measured by seeding 
equal numbers of cells onto 6-well plates in duplicates and counting cells with the 
Countess automated cell counter (Life Technologies) every 2 days until plates become 
confluent. 
Tumor sphere formation assay. Cells were plated onto ultra-low attachment 
24-well plates (Corning) in 0.8% methylcellulose (MC)-based serum-free medium (Stem 
Cell Technologies, #H4100) supplemented with 20 ng/mL epidermal growth factor (BD 
Biosciences), 10 ng/mL basic fibroblast growth factor (Sigma-Aldrich), and 5 mg/mL 
insulin (Sigma-Aldrich). The number of tumor spheres exceeding 50 µm in diameter (20 
µm for Beas-2B cells) was quantified under a light microscope after 2 weeks of culture 
under standard cell culture conditions. All experiments were performed in triplicates and 
repeated at least twice, with 5 fields of view analyzed for each replicate. 
Mouse xenograft experiments. All experiments were performed in accordance 
with the Guidelines for Animal Experiments at West Virginia University and approved by 
the Institutional Animal Care and Use Committee. Immunodeficient NOD/SCID gamma 
mice (NSG), strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Jackson Laboratory), were injected 
with 1x106 of luciferase-labeled cells subcutaneously or via the tail vein. Tumor growth 
was monitored weekly using IVIS Lumina II in Vivo Imaging system (PerkinElmer), and 
an external caliper (VWR International) was used for the subcutaneous model. Tumor 
volume was calculated using the formula: tumor volume [mm3] = 1/2 (length [mm]) × 
(width [mm]2). At the end of the experiments mice were euthanized, and their organs 
were removed and imaged ex vivo on a Petri dish to evaluate metastasis. 
Bioluminescent images were quantified using the Living Image software (PerkinElmer). 
Tissue processing and H&E staining was carried out by the WVU Pathology Laboratory 
for Translational Medicine using standard procedures. 
Immunohistochemistry. Tissue sections were deparaffinized using standard 
techniques. Antigen retrieval was carried out by heating slides in a microwave in citrate 
buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0) for 30 min. Samples were blocked 




antibodies overnight at 4 °C (specific antibodies used are listed in Supplementary Table 
1). Slides were rinsed with TBS-T buffer 3 times and incubated with fluorescently 
labeled secondary antibodies (Life Technologies) for 1 hour at room temperature; after 
which they were rinsed with TBS-T buffer 3 times and mounted with the ProLong DAPI 
(Life Technologies). Cells were visualized with a Zeiss fluorescent microscope (Carl 
Zeiss). 
Immunofluorescence. Cells were grown overnight on 8-well chamber slides 
(Nunc), fixed with 4% paraformaldehyde and permeabilized with 100% methanol at -20 
°C prior to blocking with 5% BSA in PBS. Cell were incubated with specific primary 
antibodies (listed in Supplementary Table 1), rinsed with PBS and incubated with 
secondary antibodies. Secondary antibodies were goat-anti-rabbit Alexa Fluor 546 (Life 
Technologies) and donkey-anti-mouse Alexa Fluor 488 (Jackson Immunoresearch). 
Slides were mounted with Fluoroshield with DAPI (Abcam) and visualized with a Zeiss 
fluorescent microscope (Carl Zeiss). 
RT-qPCR. Total RNA was purified using the RNeasy kit (Qiagen). Reverse 
transcription was performed with SuperScript III Reverse Transcriptase (Life 
Technologies) using oligo(dT) primers. Quantitative real-time PCR was carried out using 
the SYBR Green Master Mix (Applied Biosystems) in an ABI 7500 Real-Time PCR 
Cycler (Applied Biosystems). Results were calculated using the 2−ΔΔCt method; 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the internal control. 
Primer sequences are listed in the Supplementary Table 2. 
Statistical analysis. The data represent means ± SEM from two or more 
independent experiments as indicated. Statistical comparisons were made using two-
tailed Student's t test. When more than two groups were analyzed, ANOVA was used. 
Statistical analysis was performed with GraphPad Prism software (GraphPad), and 
p<0.05 was considered statistically significant. 
Data Availability. The datasets generated during and/or analyzed during the 













Figure 1. Human bronchial epithelial cells, chronically exposed to carbon 
nanotubes, undergo malignant transformation. (a) Chronic SWCNT-exposed 
bronchial epithelial Beas-2B (BSW) cells were cultured in soft agar for 2 weeks, and 
colonies over 50 μm in diameter were counted, n = 15, p < 0.0001, two-tailed t-test. 
Scale bar = 500 μm. (b) Luciferase-labeled cells were injected subcutaneously into 
flanks of NOD/SCID gamma mice (n=5 per group), and tumor volume was measured 
weekly by an external caliper. Means are different according to Bonferroni post hoc 
analysis following 2-way ANOVA, p < 0.05. (c) Weight of isolated subcutaneous tumors 
at week 4, p = 0.0014, two-tailed t-test. (d) Top – representative bioluminescent signal 
from tumors at week 4, Bottom – representative luciferase signal from isolated internal 
organs. (e) Luciferase signal from lungs imaged ex vivo. (f) Representative images of 
H&E stained lungs from mice bearing BSW cells. Arrows point to metastatic modules. 






Figure 2. Human bronchial epithelial cells, chronically exposed to carbon 
nanotubes, overexpress SOX9. (a) Immunoblot of BSW and control cells, showing 
significant SOX9 overexpression in BSW cells. Right – relative SOX9 expression 
presented as fold change over control cells (n = 6). Data are mean ± SEM, * - p = 
0.0347, paired two-tailed t-test. (b) Representative image of lung metastases from mice 
bearing BSW cells subcutaneously; sections were stained with anti-SOX9 antibody and 






Figure 3. SOX9 knockdown inhibits proliferative and colony-forming properties of 
BSW cells. (a) Immunoblot showing levels of SOX9 protein after knockdown generated 
by 3 different shRNAs (sh-1, sh-2, sh-3), empty vector was used as a control in BSW 
cells. (b) Rate of cell proliferation, p < 0.05, Bonferroni post hoc analysis following 2-
way ANOVA. (c) Soft agar colony formation assay. Cells were cultured in soft agar for 2 
weeks, scale bar - 500 μm. (d) Quantification of the soft agar assay, colonies larger 
than 50 μm in diameter were counted, n = 3. Data presented as mean values ± SEM. 






Figure 4. SOX9 knockdown attenuates migration and invasion of BSW cells in 
vitro. SOX9 knockdown was generated by 3 different shRNAs (sh-1, sh-2, sh-3), empty 
vector used as a control in BSW cells. BSW cells were added to control inserts 
(migration) or inserts coated with Matrigel (invasion) and incubated for 15 h. After 
removal of non-migrated and non-invaded cells, cells were fixed and stained with crystal 
violet and counted under a microscope. (a) Transwell migration assay. Bottom – 
quantification. (b) Transwell invasion assay. Bottom - quantification. Data presented as 
mean ± SEM, n =10. Means are different according to Turkey post hoc analysis 









Figure 5. SOX9 regulates cancer stem cells in SWCNT-exposed cells. SOX9 
knockdown was generated by 3 different shRNAs (sh-1, sh-2, sh-3), empty vector used 
as a control in BSW cells. (a) Tumor sphere formation assay. Right – quantitative 
analysis of tumor sphere formation, n = 15. (b) Fold change in the number of ALDHhi 
cells in SOX9 knockdown over control BSW cells, 4 independent experiments combined 
(n = 4 - 9) measured by Aldefluor assay. (c) Representative flow cytometry results for 
Aldefluor assay. Top row – cells stained with the Aldefluor substrate only, bottom – cells 
stained with the Aldefluor substrate in the presence of the specific ALDH inhibitor 
DEAB. (d) SOX9 knockdown leads to a depletion of cancer stem cell marker ALDH1A1, 
right – quantification of relative ALDH1A1 expression, fold changes over control BSW 
cells, n=3 independent experiments. Results are mean ± SEM. Means are different 










Figure 6. SOX9 knockdown inhibits BSW metastasis in vivo. Luciferase-labeled 
cells were injected intravenously via tail vein into NOD/SCID gamma mice (n=4 per 
group) and mice were imaged right after cell injection and weekly thereafter. SOX9 
knockdown was generated by 3 different shRNAs (sh-1, sh-2, sh-3), empty vector used 
as a control in BSW cells. (a) Representative whole-body bioluminescence of lung 
tumors in mice injected with control vector (BSW) or SOX9 knockdown (shSOX9-3). (b) 
Time course of lung tumor growth generated by weekly whole-body imaging, each time 
point normalized to the signal from day 0. Means are different according to Bonferroni 
post hoc analysis following 2-way ANOVA, p < 0.05. (c, e, f) Ex vivo luciferase signal 
from isolated mouse lungs, brain and liver, respectively. Means are different according 
to Turkey post hoc analysis following ANOVA. (d) Representative pictures of H&E 
stained lungs showing a notable decrease in tumor lung colonization by SOX9 
knockdown cells comparing to control cells, scale bar - 250 µm. Data are shown as 











Figure 7. SOX9 overexpression in Beas-2B cells induces stem cell-like properties. 
(a) Level of SOX9 overexpression. (b) Representative images of tumor sphere 
formation. Scale bar, 200 µm. (c) Quantitative analysis of tumor sphere formation form 
(b), n = 3, p = 0.0019, two-tailed unpaired t-test. (d) RT-qPCR analysis of 2 ALDH 
isoforms, n = 6 – 12, 2 independent experiments combined, p < 0.05 by two-tailed 
unpaired t-test. (e) Fold change in the number of ALDHhi cells in SOX9 overexpressing 
cells over control measured by Aldefluor assay, combined results from 4 independent 
experiments (n = 17), p = 0.004, two-tailed paired t-test. (f) Expression levels of stem 
cell markers were examined by RT-qPCR, n = 6 – 9, p < 0.05 according to Bonferroni 
post hoc analysis following 2-way ANOVA, GFP control vs SOX9 overexpression. n.s. - 








Table 1. Physicochemical properties of SWCNTs used in this study. 
 




Nitric acid dissolution, inductive coupled plasma-
atomic emission spectrometry (ICP-AES, NMAM 
#7300) 
% Fe (w/w) 0.23% 
Other metals Not detectable 
Surface area 400-1000 m2/g 
Nitrogen absorption-desorption technique 
(Brunauer Emmet Teller method, BET) using 
SA3100 Surface Area and Pore Size Analyzer 
(Beckman Coulter) 
Dry length, µm 0.1-1 
Field emission scanning electron microscopy 
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Supplementary Figure 1. BSW cells spontaneously metastasize in the 
subcutaneous mouse xenograft. Luciferase-labeled cells were injected 
subcutaneously into flanks of NOD/SCID gamma mice (n=5 per group). (a) Ex vivo 
bioluminescent signal from isolated mouse organs at the end of the experiment at week 
4. (b) Schematic representation of organ positions in a. (c) Ex vivo signal from liver. 







Supplementary Figure 2. SOX9 colocalizes with CSC markers. Immunofluorescence 
staining of CSC markers in SWCNT-treated and control cells. (a) Control Beas-2B cells, 
(b) BSW cells. Arrows specify cells expressing high levels of SOX9 and indicated CSC 





Supplementary Figure 3. SOX9 knockdown in H460 cells. (a) SOX9 knockdown by 3 
shRNAs diminishes ALDH1A1 expression. (b) Cell proliferation assay, n = 2. P < 0.001, 
2way repeated measures ANOVA followed by Bonferroni posttests, shRNAs vs vector 
control. (c) Soft agar colony formation. p < 0.05, Turkey post hoc analysis following 





Supplementary Table 1. List of antibodies used in this study. 
Name Company Catalog No Application 
SOX9 EMD Millipore AB5535 WB, IHC 
SOX9 EMD Millipore MABC785 IF 
ALDH1A1 Abcam ab52492 WB 
ALDH1A1 EMD Millipore MABN838 WB 
ALDH1A1 Cell Signaling 54135 IF 
β-actin Sigma-Aldrich A5441 WB 
GAPDH EMD Millipore CB1001 WB 
anti-rabbit-HRP Jackson ImmunoResearch 711-035-152 WB 
anti-mouse-HRP Jackson ImmunoResearch 715-035-151 WB 
Human mitochondria EMD Millipore MAB1273 IHC 
CD133 Cell Signaling 86781 IF 
Oct4 Abcam ab19857 IF 
WB – western blotting, IHC – immunohistochemistry, IF – immunofluorescence. 
 
Supplementary Table 2. Oligonucleotides for real-time quantitative PCR analysis. 
Name Forward (5' to 3') Reverse (5' to 3') 
ALDH1A1 AGTGTGGGTGAATTGCTATGG TGTGACTGTTTTGACCTCTGT 
ALDH1A3 CTTCTGCCTTAGAGTCTGGAAC TGCTACGTGGACAAGAACTG 
GAPDH CCCACTCCTCCACCTTTGAC ATGAGGTCCACCACCCTGTT 
CD133 TGAATAGCAACCCTGAACTGAG TTGGCGTTGTACTCTGTCAG 
Oct4 TCTTCAGGAGATATGCAAAGCAGA GATCTGCTGCAGTGTGGGT 
SOX2 CACTGCCCCTCTCACAC TCCATGCTGTTTCTTACTCTCC 







Chapter 4: General discussion and future directions 
 
The work presented in this dissertation provides an insight into the functional 
regulation of cancer cell survival during exposure to chemotherapeutic agents and 
nanomaterials. We demonstrated here that SOX9 expression is upregulated in NSCLC 
cells over the course of cisplatin treatment. Elevated SOX9 confers drug resistance by 
stimulating CSCs and upregulating the expression of a detoxifying enzyme and CSC 
marker ALDH1A1. The effect of high SOX9 expression can be blocked, at least in part, 
by pharmacological inhibition of ALDH1A1. These results suggest that activation of 
SOX9-ALDH axis in response to chemotherapy supports CSC survival. As many 
signaling pathways are known to activate SOX9 in embryogenesis and cancer initiation 
and/or progression (reviewed in Chapter 1), the exact mechanisms leading to SOX9 
upregulation by chemotherapy remain to be further elucidated. If such pathways are 
identified, targeting these in conjunction with conventional chemotherapy may present 
as an attractive treatment strategy that could overcome chemoresistance. It is worth 
noting that a short-term exposure to cisplatin (3 days) was used as a model of aquired 
resistance in this study and therefore may have limited clinical relevance as cancer 
patients usually receive several cycles of chemotherapy. However, an extended 
treatment with cytotoxic agents may lead to accumulation of novel mutations, 
particularly in artificial cell culture conditions, and therefore mask initial mechanisms of 
cellular adaptation. In addition, similar results were obtained in Chapter 3 where a long-
term treatment with carbon nanotubes induced neoplastic-like transformation and 
chemoresistance (1) concurrent with an elevated SOX9 expression in human lung 
epithelial cells, suggesting that the activation of SOX9-ALDH axis may have a broader 
role in the regulation of cellular stress responses.  
Interestingly, SOX9 also contributes to resistance to targeted and endocrine 
therapy. For example, SOX9 is upregulated in tamoxifen-resistant breast cancer cells 
and recurrent breast cancer tumors when compared to primary tumors from the same 
patients. Furthermore, SOX9 overexpression is sufficient to induce tamoxifen resistance 




a HER2 inhibitor trastuzumab in adenocarcinoma of esophagogastric junction cells (3). 
These results suggest that the role of SOX9 in chemotherapy resistance observed in 
the current work could potentially be generalized to other forms of cancer and 
therapeutic interventions including targeted drug therapy. 
The results presented in Chapter 3 complement the Chapter 2 findings utilizing a 
model of particle-induced carcinogenesis. Lung cancer is often caused by 
environmental exposure to airborne carcinogens, with cigarette smoking being the 
leading risk factor (4). However, air pollution and occupational exposure have also been 
attributed to the high incidence of lung cancer (5). With declining rates of tobacco use, 
focus of research in lung cancer should be switched or expanded to less common and 
emerging causes as they will probably be prevalent in the future. Consistently, as new 
technologies are being developed and utilized, we should anticipate new kinds of 
carcinogens to arise. Engineered nanomaterials represent one of those new materials 
that are the potential source of environmental and occupational exposure to airborne 
carcinogens. Nanomaterials are defined as substances typically between 1 and 100 nm 
in one dimension and can be naturally occurring or man-made (engineered). 
Engineered nanomaterials possess novel and unique physicochemical properties that 
provide technological advantages over conventional materials, but they can also harbor 
unknown adverse health effects, including chronic diseases such as cancer. Carbon 
nanotubes (CNTs) are one of the widely used engineered nanomaterials due to their 
unique properties, such as high durability and strength, extreme light weight and high 
electrical conductivity; however, questions about their carcinogenicity have been raised 
(6). Our group demonstrated previously that a long-term exposure to low doses of CNTs 
induces neoplastic-like transformation in bronchial and small airway epithelial cells (7, 
8). Single-walled carbon nanotube (SWCNT)-exposed Beas-2B cells exhibit elevated 
migration and invasion, anchorage-independent growth and form tumors in 
immunocompromised mice (8). Furthermore, these cells possess a highly tumorigenic 
and chemoresistant CSC population, while caveolin-1 was shown to regulate cell 




Nevertheless, metastatic properties of SWCNT-exposed lung cells are not known 
and were evaluated in this dissertation for the first time. In Chapter 3, we demonstrated 
that SOX9 expression is upregulated in lung epithelial cells chronically exposed to 
SWCNT, a model mimicking a long-term occupational and environmental exposure to 
engineered nanomaterials. We identified SOX9 as a critical player in promoting the 
metastatic and stem-like properties of these cells. We also observed a correlation 
between SOX9 levels and ALDH expression and activity. Taken together, the findings in 
both chapters support the versatile role of SOX9 in regulating cell survival after 
exposure to various toxic agents.  
CSCs have been implicated in cancer dissemination, drug resistance and 
recurrence (10). Thus, it is critical to elucidate CSC-specific signaling pathways and 
biomarkers. Unfortunately, CSCs represent a highly plastic cell population that is 
extremely difficult to study and, more importantly, to target for therapeutic intervention. 
Furthermore, CSCs are often identified and isolated based on the same markers that 
are expressed in normal adult stem cells. Hence, it not surprising that multiple efforts to 
target CSCs in clinical settings have failed (11). The results presented in this 
dissertation identify one of the pathways in CSC activation under the specific conditions 
of short-term cisplatin treatment and long-term carbon nanotube exposure. High SOX9 
expression in these situations may be used as a marker for functional activation of 
CSCs to identify high risk populations or patients who might benefit from CSC-targeted 
therapy. 
Interestingly, most studies on SOX9 functions reported decreased cell 
proliferation in SOX9 knockdown cells and increased proliferation in SOX9 
overexpressing cells, i.e. in prostate (12) and lung cancers (13). We similarly observed 
decreased cell proliferation in SOX9 knockdown cells, but an opposite effect in 
overexpressing cells, i.e. decreased proliferation, suggesting that an optimal SOX9 
expression is required for cancer cell proliferation. This finding is supported by previous 





With regards to mechanistic studies, we focused our attention on the functional 
linkage of ALDH1A1 and drug response as well as CSC properties since some 
information on this enzyme function was already available but required more in-depth 
investigation. Moreover, little is known about the role of other ALDH isoforms in cancer, 
and the biological functions of some isozymes are virtually unknown (17) (Table 3 in 
Chapter 1). Interestingly, several ALDH enzymes share preferred substrates and exhibit 
some degree of functional redundancy (18). Thus, ALDH1A1 may not be the only 
isoform involved in chemoresistance or under the regulation of SOX9. Future studies 
could include identification of specific ALDH isoforms contributing to drug resistance of 
NSCLC. This could be achieved by screening drug-resistant cells for the expression of 
all ALDH isoforms and confirming the results by knocking the potential candidate 
proteins down individually to evaluate changes in drug responses. However, this 
approach has several limitations. First, a knockdown of one ALDH isoform may not 
have a profound effect on drug sensitivity due to redundancy between these isozymes 
(19, 20). Second, it is difficult to evaluate enzymatic activity of every isoform due to the 
lack of specific inhibitors and assessment methods, while the enzyme expression levels 
may not serve as a precise measurement of their functionality. In fact, ALDH1A1 activity 
was shown to be regulated post-transcriptionally by acetylation (21) and 
phosphorylation (22). Current methods for measuring cellular ALDH activity include flow 
cytometry-based Aldefluor® assay (23) and spectrophotometric quantification of NADH 
accumulation (24); however, both techniques are not isoform-specific. Aldefluor® relies 
on an ALDH inhibitor DEAB which inhibits several ALDH isoforms (25, 26). Zhou et al. 
previously showed that 9 out 19 human ALDH enzymes can contribute to Aldefluor® 
results, including ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, 
ALDH3A2, ALDH3B1, and ALDH5A1 (27). While several selective ALDH1A1 inhibitors 
have been reported recently (28-30), the situation with specific inhibitors for other 
isozymes remains unresolved. Nevertheless, a pan-ALDH1 inhibitor showed promising 
results in preclinical models of ovarian cancer (31). Disulfiram, a drug widely used in 
alcoholism treatment, inhibits ALDH1A1, ALDH2, and several CSC signaling pathways 
(32), promoted overall survival (10 vs. 7.1 months) when administered with 




Therefore, identification of cancer type-specific ALDH isoforms contributing to drug 
resistance and the corresponding inhibitors could lead to more effective and 
personalized treatments with reduced side effects. 
Another avenue for clinical applications of this work would be targeting K-ras-
mutated tumors. It was demonstrated that oncogenic K-ras upregulates SOX9 
expression and activity in pancreatic ductal adenocarcinoma (PDAC) (34). Additionally, 
SOX9 expression is increased in K-ras mutated lung adenocarcinomas and in a 
KrasG12D mouse model for lung adenocarcinoma (35). K-ras driver-mutations are 
currently not druggable by targeted therapy but are identified in up to 25% of human 
lung adenocarcinomas (36), hence, pharmacologic intervention at the level of SOX9 
and/or ALDH may be a promising treatment strategy to pursue.  
Further studies are also needed to evaluate how broadly SOX9 activates the 
CSC survival program. ChIP-seq would a logical next step to identify additional proteins 
participating in this program. However, only a few direct transcriptional targets of SOX9 
have been identified thus far, probably because SOX9 operates in collaboration with 
other factors to regulate transcription, and because this cooperation may be tissue 
specific or context dependent (37, 38). Hence, more studies are warranted to identify 
the molecular machinery governing CSC survival under these cellular stress conditions. 
The current work investigated the molecular mechanisms of CSC regulation 
under drug and particle-induced cellular stress using established lung cell lines. 
Additional studies in other cell systems and in vivo will be needed to validate the results. 
To that end, mice bearing NSCLC cells or patient derived tissues can be exposed to 
chemotherapy drugs and then tumors analyzed for SOX9 expression. Chemotherapy 
treatment in combination with an ALDH inhibitor could be used to validate our in vitro 
results. However, most available ALDH inhibitors are not entirely specific to ALDH1A1 
but also affect other isoforms, although several new isozyme-specific inhibitors are 
being developed and have been reported (30, 39, 40). 
However, xenograft mouse models do not fully recapitulate all aspects of 




tumor microenvironment. Several existing transgenic mouse models could be used to 
overcome this limitation. For instance, Lox–Stop–Lox K-ras conditional mouse strain 
(LSL-K-rasG12D), in which the expression of endogenous levels of oncogenic K-ras is 
controlled by a removable transcriptional termination stop element, forms adenomas 
and adenocarcinomas (41). SOX9 can be removed conditionally by breeding K-rasG12D 
with Sox9flox/flox mice (42). SOX9 deletion can be performed at the same time as 
activation of oncogenic K-ras through the administration of an engineered Adeno-Cre 
virus via intratracheal instillation. I expect a delayed and/or reduced tumor initiation in 
this mouse model but SOX9 removal may not be sufficient to completely inhibit 
tumorigenesis due to functional redundancy in oncogenic signaling pathways. Similar 
results were observed in PDAC where malignant lesions were formed only from cells 
that retained SOX9 expression due to limitations in recombination efficiency (43). One 
of the possible ways to avoid incomplete transgene recombination is to generate SOX9 
knockout in LSL-K-rasG12D mice by lentivirus transduction. CRISPR/Cas9-sgSOX9 
lentivirus delivered through intratracheal administration would induce double-strand 
DNA breaks in the same lung cells that undergo activation of the mutant Kras. 
LSL-K-rasG12D model is widely used to generate early stage cancer, however, 
mouse models for late stage and metastatic lung cancer would be more clinically 
relevant as the majority of NSCLC patients are diagnosed when cancer has already 
metastasized (44). LSL-K-rasG12D; p53Flox mice develop advanced adenocarcinomas 
with local invasion and metastases to lymph nodes and distant organs (45, 46). 
CRISPR/Cas9-sgSOX9 lentivirus delivered intratracheally to these animals is supposed 
to reduce tumor formation and metastasis as compared to mice received sgControl 
virus. Another interesting use of the same model is to investigate metastatic properties 
of SOX9 without affecting primary tumors. In this case, LSL-K-rasG12D; p53Flox mice can 
be crossed with CCSP-rtTA/(teto)7-CMV-shSOX9 mice (not available yet to my 
knowledge), where the reverse tetracycline trans-activator protein (rtTA) is expressed 
under Clara cell secretory protein (CCSP) promoter (47). Therefore, activation of the 
mutant Kras and p53 deletion will be stimulated by Adeno-Cre virus via an intratracheal 
instillation, allowing for primary tumor formation. SOX9 knockdown can be induced by 




induction of primary tumors. These experiments would shed light on the role of SOX9 in 
the initiation of metastasis and would elucidate SOX9-dependent metastatic events and 
their timing. SOX9 overexpression experiments could be performed in the same lung 
cancer models to support the results of SOX9 knockout. Overexpression studies could 
be accomplished by using SOX9 knockin mice CAG-mRFP1flox-Sox9-EGFP (CAG-
Sox9) (48). Doxycycline-inducible lentiviral particles with SOX9 expression constructs 
can be used if we want to disconnect the timing of tumor initiation and SOX9 
overexpression.  
In summary, this dissertation work identified SOX9 as a critical regulator of CSC 
survival in drug and particle-exposed human lung cells, and provided evidence that it 
acts, at least in part, through transcriptional activation of ALDH1A1. The SOX9-ALDH 
axis could have a broad role in regulating CSC survival under diverse cellular stress 
conditions and in various cancer types. More studies are still needed to evaluate the 
upstream signaling pathways and other downstream effectors of SOX9 for better 
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